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ABL Abelson oncogene
AIDS acquired immunodeficiency syndrome
ASPL alveolar soft part sarcoma chromosome region, candidate gene 1
ASPS alveolar soft part sarcoma
ATF1 activating transcription factor 1 gene
ATM ataxia telangiectasia mutated gene
bp base pairs
BCL1 B-cell leukemia/lymphoma-1 gene
BCR breakpoint cluster region gene
BRCA1, 2 breast cancer, early onset, genes 1 and 2
CCND1 cyclin D1 gene (alias: PRAD1)
CDK4 cyclin-dependent kinase 4 gene
CGH comparative genomic hybridization
CML chronic myeloid leukemia
COL1A1 collagen type I alpha 1 gene
DAPI 4’,6-diamino-2-phenylindole
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DDIT3 DNA-damage-inducible transcript 3 (alias: CHOP10)
DFSP dermatofibrosarcoma protuberans
DNA deoxyribonucleic acid
EBV Epstein-Barr virus
EMS1 mammary tumor and squamous cell carcinoma-associated gene
ERG v-ets avian erythroblastosis virus E26 oncogene-related gene
ETS Ewing’s sarcoma translocation genes
ETV1, 4, 6 ETS variant genes 1, 4, and 6
EWS Ewing’s sarcoma breakpoint region 1 gene
FGF3 fibroblast growth factor 3 gene (alias: INT2)
FGF4 fibroblast growth factor 4 gene
FISH fluorescence in situ hybridization
FITC fluorescein isothiocyanate
FKHR forkhead homolog 1 gene
FLG filaggrin gene
FLI1 Friend leukemia virus integration 1 gene
FS-DFSP fibrosarcomatously transformed dermatofibrosarcoma protuberans
FUS translocated in liposarcoma gene
GAS gastric cancer gene
GIST gastrointestinal stromal tumor 
GLI glioma-associated oncogene homolog gene
HBV hepatitis B virus
HCV hepatitis C virus
HHV-8 human herpesvirus 8
HIV human immunodeficiency virus
HSCT hyalinizing spindle cell tumor with giant rosettes
HTLV-1 human T-cell leukemia virus type I
INT2 murine mammary tumor virus integration site (v-int-2) oncogene homolog
gene (alias: FGF3)
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog gene
9KSHV Kaposi’s sarcoma-associated herpesvirus, HHV-8
LED lupus erythematosus disseminatus
LGFMS low-grade fibromyxoid sarcoma
LMS leiomyosarcoma
Mb megabase
MDM2 human homolog of murine double minute 2 gene
MFH malignant fibrous histiocytoma
MMTV mouse mammary tumor virus
MPNST malignant peripheral nerve sheath tumor
NR4A3 nuclear receptor subfamily 4, group A, member 3 gene
NTRK1, 3 neurotrophic tyrosine kinase receptor genes, types 1 and 3
PAT1 amyloid beta precursor protein-binding protein 2 gene
PAX 3, 7 paired box homeotic genes 3 and 7
PDGFB platelet-derived growth factor beta polypeptide gene
PRAD1 parathyroid adenomatosis 1 gene (alias: CCND1)
PS6K ribosomal protein polypeptide gene
RAD51C homolog C of S. cerevisiae RAD51 gene
RB1 retinoblastoma gene
SAS sarcoma amplified sequence gene
SIGMA1B adaptor-related protein complex 1, sigma 2 subunit gene
SPRR3 small proline-rich protein 3 gene
SSX1, 2, 4 synovial sarcoma, X breakpoint genes 1, 2, and 4
SYT synovial sarcoma translocation gene
TAF2N TATA box binding protein-associated factor 2N gene
TBX2 T-box 2 gene
TFE3 transcription factor for immunoglobulin heavy-chain enhancer 3 gene
TP53 tumor protein 53 gene
TRITC tetra-rhodamine isothiocyanate
WT1 Wilms tumor 1 gene
YAC yeast artificial chromosome
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3. ABSTRACT
The identification of genetic abnormalities in many human tumor types has led to
tremendous growth in our understanding of tumorigenesis. This thesis contributes to
research on soft tissue sarcomas, particularly rare types, by its use of novel molecular
cytogenetic methods, which make it possible to study archival samples and to analyze
even the very complex genetic aberrations commonly seen in soft tissue sarcomas.
Genetic alterations in 13 alveolar soft part sarcomas (ASPS), 11 low-grade fibromyxoid
sarcomas (LGFMS), 12 Kaposi's sarcomas, 19 dermatofibrosarcoma protuberances
(DFSP), and 28 Ewing tumors were studied by the recently developed comparative
genomic hybridization method. The Kaposi’s sarcoma tumors were further studied by
interphase fluorescence in situ hybridization (FISH) and immunohistochemistry.
No recurrent specific DNA copy number alterations were found in the ASPS
tumors. In one of the tumors, gain of Xp11-pter was recognized, probably reflecting the
presence of the recently discovered specific unbalanced translocation
der(17)t(X;17)(p11;q25).
 Of the 11 LGFMS tumors, six presented with a DNA copy number loss of 13q21-
q22. This exceptionally high incidence (55%) may suggest an important role for a tumor
suppressor gene(s), located at 13q21-q22, in this particular tumor type.
 A recurrent, restricted gain of 11q13, was identified as being present in four
Kaposi’s sarcomas. This area harbors several known oncogenes, of which two, FGF4
and INT2, were considered to be of special interest in this context. The amplification of
FGF4 and INT2 was therefore further studied by interphase FISH with YAC probes
carrying both genes. The genes were found to be amplified. The expression of these
genes was studied by immunohistochemistry, which revealed immunoreactivity with
both anti-FGF4 and anti-INT2. These experiments showed that both FGF4 and INT2
were amplified and expressed in Kaposi’s sarcoma, possibly contributing to the
pathogenesis.
Gains or amplifications of 17q21-qter and 22pter-q13 were found in 100% and
79% of the DFSP tumors, respectively. The starting points of the gains or amplifications
coincided in many cases with the breakpoints of the DFSP-specific translocation
t(17;22)(q22;q13). Although the translocation, often located in supernumerary ring
chromosomes creating amplification of the chromosomal segments involved, is
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considered to be the tumorigenetic event, the consistency of the gains may imply an
important primary role in DFSP pathogenesis for genes located at 17q21-qter and
22pter-q13.
The possible role of DNA copy number changes in DFSP tumor progression was
evaluated by comparing the DNA copy number alterations of typical DFSP tumors to the
alterations of DFSP tumors with areas of fibrosarcomatous transformation, which is
considered to represent tumor progression. No significant differences were noted
between the two groups, suggesting mechanisms other than copy number alterations to
be more important in DFSP progression.
The most recurrent copy number alterations found in the Ewing tumors were
statistically tested for possible correlations with clinical parameters. DNA copy number
increases of 1q21-q22, of chromosome 8, and of chromosome 12 were associated with
trends towards worse prognosis, but no statistically significant correlations were
reached. Gain or high-level amplification of 6p21.1-pter correlated significantly with
worse prognosis. Because the patients with this aberration had, however, clinical signs
with poor prognosis, the independent relevance of 6p21.1-pter gain as a prognostic
marker remains to be confirmed.
Characterization of genomic areas comprising DNA copy number losses or gains
will potentially affect the biological and clinical assessment of soft tissue sarcomas, and
novel findings of genetic changes can allow the design of molecularly targeted
treatments.
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4. INTRODUCTION
All malignant neoplasms are known to be caused by genetic aberrations. These
aberrations include deletions, translocations, inversions, and amplifications which
disrupt normal functions of cellular oncogenes, tumor suppressor genes, mismatch
repair genes, and other genes like those involved in cell apoptosis. In most cancer
cases, accumulation of various alterations in the cellular DNA is needed for malignant
transformation (Vogelstein & Kinzler, 1993). Many malignant diseases have already
been genetically well characterized, and cytogenetic as well as molecular genetic
methods have been successfully applied in their diagnostic assessment. This is
particularly true for hematological malignancies, the clinical evaluation of which today
routinely includes genetic analysis (Clare & Hansen, 1994).
Soft tissue sarcomas are a heterogeneous group of malignant connective tissue
tumors of mesodermal or neuroectodermal origin. The spectrum of tumors in this entity
is broad, which makes differential diagnosis and tumor classification a challenging task.
Cytogenetically, soft tissue sarcomas frequently carry complex aberrations; this poses
difficulties for analyzing the tumors by conventional cytogenetic approaches
(Sreekantaiah et al., 1994).
Since especially the rarer soft tissue sarcomas frequently present noticeable
diagnostic problems, and even many of the better-characterized tumors still lack reliable
prognostic markers, new specific molecular genetic markers are expected to become
increasingly useful in the clinical evaluation of such tumors. In addition to the diagnostic
and prognostic impact, identification of new genetic events in the disease process will
increase our understanding of the biology of cancer development and progression. This
will ultimately reveal new therapeutic targets, as has already eventuated in treatment for
chronic myeloid leukemia (Druker et al., 2001b). This research aims at increasing the
understanding of genetic alterations involved in the pathogenesis of rare soft tissue
sarcomas, and contributes to providing new prospects for their biological as well as
clinical perception.
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5. REVIEW OF THE LITERATURE
5.1. GENERAL CHARACTERISTICS OF SOFT TISSUE SARCOMAS
Soft tissue sarcomas can be defined as malignant tumors arising from nonepithelial
extraskeletal tissues of the body, exclusive of the reticuloendothelial system, glia, and
supporting tissue of parenchymal organs. Embryologically, soft tissue sarcomas are
principally derived from the mesoderm, with some contribution from the neuroectoderm.
They comprise malignant neoplasms of voluntary muscles, fat, fibrous tissue, and the
vessels serving these tissues (Enzinger & Weiss, 1995).
Soft tissue sarcomas are clinically and histologically a highly heterogeneous
group of tumors, some exhibiting only local aggressivity, others showing extensive
metastatic potential. Their classification has earlier predominantly been based on the
nuclear configuration of the tumor cells, thus providing a mainly descriptive
classification. Currently, the more informative classifications used are based principally
on the line of differentiation of the tumor, that is, the resemblance of the tumor tissue to
normal adult tissue (Weiss, 1994). For clinical purposes, additional information is
provided by staging and grading, which allow more accurate definition of the prognosis
and planning of therapy. Other factors affecting prognosis include age and sex of the
patient, as well as location of the tumor (Levine, 1999). The overall 5-year survival rates
vary from less than 50% to over 80% depending on these factors (Lawrence et al., 1987;
Pisters & Pollock, 1999; Russell et al., 1977; Rydholm et al., 1999).
Soft tissue sarcomas are relatively uncommon. Annually, the incidence rate is
about one to two cases per 100 000 population (Hashimoto, 1995). In Finland around
130 new cases are diagnosed every year, and of all new cancer cases, less than 1%
represent soft tissue sarcomas. The most common histological soft tissue sarcoma
types - malignant fibrous histiocytoma (MFH), liposarcoma, leiomyosarcoma (LMS), and
synovial sarcoma - comprise the majority of all cases among the over 50 histological
entities recognized (Figure 1) (Bauer et al., 1999; Hashimoto, 1995; Kransdorf, 1995).
The apparent difficulties in diagnostics and classification are illustrated by the
substantial proportion of unclassified cases; as many as 5 to 10% of all soft tissue
sarcomas fall into this category. Soft tissue sarcomas occur more commonly in males,
and in the middle-aged and elderly, but distinct histological types show different sex and
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age distributions. For example, MFH is typically a tumor of middle and old age, whereas
rhabdomyosarcoma occurs almost exclusively among young patients. The anatomic
location most often involved is the lower extremities, the thigh being the most frequent
site, followed by the retroperitoneum, mesentery, and trunk (Bauer et al., 1999;
Hashimoto, 1995; Kransdorf, 1995).
Figure 1. Mean frequency distribution of soft tissue sarcoma types according to
Hashimoto (Hashimoto, 1995) and Kransdorf (Kransdorf, 1995). Incidences vary
among the series; in the Scandinavian Sarcoma Group Register, MFH accounts for
approximately 40% of all soft tissue sarcomas (Bauer et al., 1999).
The etiology or pathogenesis of soft tissue sarcomas, as of other types of
malignant neoplasms, is still unknown. Benign soft tissue tumors rarely evolve into
sarcomas, except for plexiform neurofibromas of patients with type 1 neurofibromatosis,
which sometimes give rise to malignant schwannomas (malignant peripheral nerve
sheath tumors, MPNST) (King et al., 2000). Evaluation of the causal factors in soft tissue
sarcoma pathogenesis is difficult, since the period between the potential exposure and
detection of the tumor is long, and various environmental and hereditary variables may
effect simultaneously. Risk factors like radiation, viral infections, immunodeficiency, and
dioxin exposure have, however, been recognized.
 Ionizing radiation can induce many types of malignancies, including soft tissue
sarcomas, by generating DNA damage. The most common post-radiation soft tissue
8%  Extraskeletal Ewing
tumors 1%
 Kaposi's sarcoma 1%
 LGFMS <1%
 ASPS <1%
 DFSP 4%
Malignant fibrous histiocytoma 24%
Liposarcoma 13%
Leiomyosarcoma 9%
Synovial sarcoma 7%
Malignant schwannoma 6%
Rhabdomyosarcoma 6%
Fibrosarcoma 5% Undetermined 7%
Other types 15%
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sarcoma is MFH, accounting for the majority of radiation-induced soft tissue sarcomas.
Post-radiation sarcomas, although rare, appear to be associated with poorer prognosis
than their sporadic counterparts (Davidson et al., 1986; Enzinger & Weiss, 1995; Laskin
et al., 1988; Robinson et al., 1988; Wiklund et al., 1991).
Viruses are associated with a variety of human malignancies: hepatitis B virus
(HBV) and hepatitis C virus (HCV) with hepatocellular carcinoma; Epstein-Barr virus
(EBV) with Burkitt’s lymphoma, nasopharyngeal carcinoma, Hodgkin’s disease, and
childhood LMS; and human T-cell leukemia virus type I (HTLV-1) with adult T-cell
leukemia. In addition, several candidate tumor viruses have been suggested, including
human herpesvirus 8 (HHV-8), the role of which in the pathogenesis of Kaposi’s
sarcoma is currently under intensive research (Beral & Newton, 1998; Boman et al.,
1997; Butel, 2000; Hill et al., 1997; Rogatsch et al., 2000; Schulz & Moore, 1999).
Dioxin exposure belongs among the environmental factors implicated in soft
tissue sarcoma etiology, but the exposure time and level as well as the latent period are
still equivocal (Bertazzi et al., 1997; Fingerhut et al., 1984; Saracci et al., 1991).
The genetic factors causing hereditary susceptibility for soft tissue sarcomas are
discussed in a subsequent chapter.
5.2. GENERAL CHARACTERISTICS OF SARCOMAS STUDIED IN THIS WORK
Alveolar soft part sarcoma
Alveolar soft part sarcoma (ASPS) was first described as a distinct entity in 1952
(Christopherson et al., 1952). It is a rare tumor making up less than 1% of all soft tissue
sarcomas. ASPS is typically a tumor of children and young adults, with female
preponderance, occurring in a variety of anatomic locations (Hashimoto, 1995;
Lawrence et al., 1987). The cellular nature of ASPS is poorly known. Several theories
have existed as to the nature of ASPS, of which skeletal muscle differentiation has
received the most convincing evidence (Auerbach & Brooks, 1987; DeSchryver-
Kecskemeti et al., 1982; Miettinen & Ekfors, 1990b; Mukai et al., 1986; Nakano et al.,
2000). Although the clinical course of ASPS is slow, eventually most of the patients
develop metastases. The approximate median survival rate ranges from 3 to 11 years,
depending on whether metastasis is present at diagnosis (Lieberman et al., 1989).
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Low-grade fibromyxoid sarcoma
Low-grade fibromyxoid sarcoma (LGFMS) was described by Evans in 1987. Ten years
later, a closely similar tumor, the hyalinizing spindle cell tumor with giant rosettes
(HSCT), was characterized and later suggested to represent the same entity as LGFMS
(Folpe et al., 2000; Lane et al., 1997).  Because fewer than 100 cases of LGFMS have
been reported, its incidence thus far remains unknown. LGFMS is a benign-appearing
tumor typically occurring in deep soft tissues of young adults, but is reported also in
children. This tumor was initially described as aggressive, and the death rate was
suggested to be close to 20% (Devaney et al., 1990; Evans, 1993; Goodlad et al., 1995).
Recently, however, more favorable figures have been proposed for metastasis and
tumor-related deaths, possibly due to better recognition of LGFMS in the initial
diagnostic evaluation of these patients. In addition to better diagnostics, classification of
this tumor type will also affect its prognosis, since HSCT is rarely a metastatic tumor
(Folpe et al., 2000; Lane et al., 1997).
Kaposi’s sarcoma
Kaposi’s sarcoma is a vascular tumor presenting in different clinico-pathological and
epidemiological forms. The classical Kaposi’s sarcoma has a prolonged, indolent
course, affects mainly the extremities of elderly men, and is prevalent in certain parts of
the world where it is endemic: the Mediterranean area and certain parts of Africa. In
Central Africa, Kaposi’s sarcoma may have accounted for up to 9% of all reported
malignant neoplasias even before the acquired immunodeficiency syndrome (AIDS)
epidemic (Safai & Good, 1981). The lymphadenopathic form of Kaposi’s sarcoma is
more rare, occurring primarily in young African children, with a less evident male
preponderance. This form engages primarily the lymph nodes and has an aggressive
clinical course (Desmond-Hellmann & Katongole-Mbidde, 1991). The
immunosuppression-associated form of Kaposi’s sarcoma occurs in adults and
children undergoing immunosuppressive treatment, usually in a post-transplant
situation. The course of the disease is dependent on immunosuppression level, and the
lesions may regress after discontinuation of therapy. The incidence of post-
transplantation Kaposi’s sarcoma in Western countries has been estimated at less than
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1% (Harwood et al., 1979; Qunibi et al., 1993). The AIDS-related form is the most
prevalent, in the USA affecting up to 15 to 20% of 30- to 38-year-old homosexual or
bisexual men with AIDS. The risk in other human immunodeficiency virus (HIV)
transmission groups, such as hemophiliacs and drug addicts, has been less than 5%.
Kaposi’s sarcoma is the most common AIDS-related neoplasm, often manifesting as a
disseminated, rapidly progressing disease in young adults (Beral, 1991; Desmond-
Hellmann & Katongole-Mbidde, 1991).
Its epidemiological characteristics have suggested an infectious factor important
in Kaposi’s sarcoma etiology. Recent studies have strengthened this hypothesis, since
a novel herpesvirus, HHV-8 or Kaposi’s sarcoma-associated herpesvirus (KSHV), was
identified and found to be present in all forms of Kaposi’s sarcoma (Chang et al., 1994;
Martin et al., 1998; Warmuth & Moore, 1997; Whitby et al., 1995). HHV-8 encodes several
homologs of human genes with contribution to cellular signaling and regulatory
pathways, but the exact roles of these genes in the transformation process remain to be
defined (Boshoff & Chang, 2001).
Dermatofibrosarcoma protuberans
Dermatofibrosarcoma protuberans (DFSP) accounts for a few percent of all soft tissue
sarcoma cases (Hashimoto, 1995). DFSP is a slow-growing, low-grade malignancy with
a tendency for local recurrence, but a low potential for metastasis. It is typically a tumor of
young to middle-aged adults, seen mainly on the trunk and the proximal extremities
(Taylor & Helwig, 1962). A subset of DFSP tumors shows areas with fibrosarcomatous
transformation (FS-DFSP), transformation considered a form of tumor progression
associated with a significantly more aggressive clinical course: only 1% of the typical
DFSP tumors metastasize, whereas in FS-DFSP cases metastases and tumor-related
deaths have been reported in more than 10% and 5% (Mentzel et al., 1998).
Ewing tumors
Ewing’s sarcoma and the closely related peripheral primitive neuroectodermal tumors,
collectively often referred to as the Ewing tumors, can arise in bone or soft tissue. These
tumors are typically found in children, adolescents, and young adults, with a median age
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of 20 years, and account for approximately 14% of bone sarcomas and 2 to 3% of
malignant soft tissue tumors (Bauer et al., 1999; Harms, 1995; Hashimoto, 1995).
Ewing’s sarcoma is a highly malignant disease, but with modern therapy its prognosis
has improved, with 5-year survival rates over 50% reported(Elomaa et al., 2000; Schmidt
et al., 1991).
5.3. GENETIC ABERRATIONS INVOLVED IN SOFT TISSUE SARCOMA AND EWING
TUMORS
Cytogenetic changes
Cytogenetic studies have revealed chromosomal aberrations in practically all soft tissue
sarcoma types. The aberrations include primary, tumor-specific alterations, which can
be considered to reflect underlying gene defects, which have an important role in the
tumorigenesis. Secondary changes are less specific, and often play an important role in
tumor progression. More random, often multiple different changes, also appear,
reflecting the genetic instability of the tumor (Mitelman, 1996; Nilbert, 1997).
Cytogenetically, several types of soft tissue sarcomas are characterized by
specific chromosomal translocations, which, in addition to the sarcomas, are typical and
often well characterized in hematological malignancies, but appear uncommon in
carcinomas (Åman, 1999). Chronic myeloid leukemia (CML) is a classic example of a
hematological malignancy with a specific translocation: The t(9;22), cytogenetically seen
as the Philadelphia (Ph) chromosome, forms a fusion gene, BCR-ABL, encoding a
protein with deregulated tyrosine kinase activity. Recently, very impressive treatment
results have been achieved with a synthetic inhibitor of the activated tyrosine kinase
(Druker et al., 2001a; Druker et al., 2001b). This inhibitor, known as STI571, appears to
be extremely efficient and well tolerated. This represents the first example of a therapy
specifically targeted to the malignancy-causing gene defect.
In addition to hematological malignancies, many of the specific translocations in
soft tissue sarcomas have also been further described at molecular level (Table 1). In
general, these translocations join together segments of two genes, forming novel fusion
genes which often give rise to aberrant transcription factors (Fletcher, 1994). Specific
translocations have been shown to be of clinical value in several instances in evaluation
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of soft tissue sarcomas. In liposarcoma, the distinction between different histological
subtypes, as well as differential diagnosis between liposarcoma and other sarcomas,
can be facilitated by the presence of the characteristic translocations t(12;16)(q13;p11)
and t(12;22)(q13;q12) in the myxoid and round cell subtypes of liposarcoma
(Panagopoulos et al., 1996; Turc-Carel et al., 1986).
Table 1. Specific translocations in sarcomas
Tumor Translocation Affected genes1 References
Alveolar soft part sarcoma t(X;17)(p11;q25) TFE3/ASPL (Ladanyi et al., 2001)
Congenital fibrosarcoma t(12;15)(p13;q25) ETV6/NTRK3 (Knezevich et al., 1998)
Desmoplastic small round cell
tumor
t(11;22)(p13;q12) WT1/EWS (Ladanyi & Gerald, 1994)
Dermatofibrosarcoma
protuberans
t(17;22)(q22;q13) COL1A1/PDGFB (Simon et al., 1997)
Ewing tumors (Ewing’s
sarcoma, Askin tumor, and
peripheral primitive
neuroectodermal tumors)
t(11;22)(q24;q12)
t(21;22)(q22;q12)
t(7;22)(p22;q12)2
t(17;22)(q21;q12)2
t(2;22)(q33;q12)2
FLI1/EWS
ERG/EWS
ETV1/EWS
ETV4/EWS
FEV/EWS
(Delattre et al., 1992)
(Zucman et al., 1993b)
(Jeon et al., 1995)
(Kaneko et al., 1996)
(Peter et al., 1997)
Extraskeletal myxoid
chondrosarcoma
t(9;22)(q22;q12)
t(9;17)(q22;q11)
NR4A3/EWS
NR4A3/TAF2N
(Labelle et al., 1995)
(Panagopoulos et al., 1999)
Liposarcoma myxoid and
round cell
t(12;16)(q13;p11) DDIT3/FUS (Rabbitts et al., 1993)
(Knight et al., 1995)
Rhabdomyosarcoma, alveolar t(2;13)(q35;q14)
t(1;13)(p36;q14)
PAX3/FKHR
PAX7/FKHR
(Galili et al., 1993)
(Davis et al., 1994)
Synovial sarcoma t(X;18)(p11.2;q11.2) SSX1/SYT
SSX2/SYT
SSX4/SYT
(Clark et al., 1994)
(Crew et al., 1995)
(Skytting et al., 1999a)
Soft tissue clear cell sarcoma
(Malignant melanoma of the
soft parts)
t(12;22)(q13;q12) ATF1/EWS (Zucman et al., 1993a)
1 abbreviations for genes: TFE3, transcription factor for immunoglobulin heavy-chain enhancer 3
gene; ASPL, alveolar soft part sarcoma chromosome region, candidate 1; ETV1, 4, and 6, ETS
variant genes 1, 4, and 6; NTRK3, neutrotrophic tyrosine kinase receptor type 3 gene; WT1,
Wilms tumor 1 gene; EWS, Ewing’s sarcoma breakpoint region 1 gene; COL1A1, collagen type I
alpha 1 gene; PDGFB, platelet-derived growth factor beta polypeptide gene; FLI1, Friend leukemia
virus integration 1 gene; ERG, v-ets avian erythroblastosis virus E26 oncogene related gene;
NR4A3, nuclear receptor subfamily 4, group A, member 3 gene; TAF2N, TATA box binding
protein-associated factor 2N gene; DDIT3, DNA-damage-inducible transcript 3 gene; FUS,
translocated in liposarcoma; PAX 3 and 7, paired box homeotic genes 3 and 7; FKHR, forkhead
homolog 1 gene; SSX1, 2, and 4, synovial sarcoma, X breakpoint genes 1, 2, and 4; SYT, synovial
sarcoma translocation gene; ATF1, activating transcription factor 1 gene
2 described in Ewing’s sarcoma but not in other tumors of the Ewing tumor group
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In synovial sarcoma, most tumors present with t(X;18)(p11.2;q11.2), which, at the
molecular level, has been found to include three alternative gene rearrangements: The
SYT gene at 18q11.2 is fused with either the SSX1, SSX2, or SSX4 gene at Xp11.2.
Identification of different fusion genes in synovial sarcoma has been suggested to be of
prognostic value, but the specificity of the translocation was recently questioned by
O’Sullivan et al., who found the SYT-SSX fusion in a substantial number of MPNSTs
(Clark et al., 1994; de Leeuw et al., 1995; Inagaki et al., 2000; Nilsson et al., 1999;
O'Sullivan et al., 2000; Skytting, 2000; Skytting et al., 1999a).
The Ewing tumors are characterized by translocations that fuse the EWS gene on
chromosome 22q12 with one of the members of the ETS family of transcription factors:
FLI1 (11q24), ERG (21q22), ETV1 (7p22), ETV4 (17q21), or FEV (2q33). Because these
translocations are not specific to clinical features, fusions of different ETS genes to EWS
can thus be present in phenotypically similar tumors (Delattre et al., 1992; Jeon et al.,
1995; Kaneko et al., 1996; Peter et al., 1997; Zucman et al., 1993b). The EWS gene is
also involved in several other translocations, leading to the fusion of different DNA-
binding proteins to EWS, and thus generating distinct tumor phenotypes (Table 1).
In certain soft tissue sarcoma types, ring chromosomes are a frequent finding,
sometimes as part of a complex karyotype, but they may also be seen as recurrent
aberrations in noncomplex karyotypes, suggesting their pathogenetic role. As sole
aberrations or as part of noncomplex karyotypes, ring chromosomes have been reported
in MFH, atypical lipoma, well-differentiated liposarcoma, and DFSP, and recently in a
case of LGFMS, all of these being low-grade types of soft tissue sarcoma (Bridge et al.,
1990; Fletcher et al., 1996; Heim et al., 1988; Mandahl et al., 1990; Mezzelani et al., 2000;
Rosai et al., 1996; Örndal et al., 1992). Ring chromosomes are mitotically unstable.
They show both inter- and intracellular variation in structure and number, thus providing
an effective means for gene amplification, yet in other types of malignancies they appear
to be rare (Gisselsson et al., 1999).
In DFSP, the rings contain material from chromosomes 17 and 22, and low-level
amplification of segments from 17q and 22q has been demonstrated in association with
the rings (Minoletti et al., 1995; Pedeutour et al., 1994; Pedeutour et al., 1995). The rings
have been shown to carry a specific translocation t(17;22)(q22;q13) which results in the
fusion of the collagen type I alpha 1 (COLIA1) gene with the platelet-derived
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growth factor B-chain (PDGFB) gene, releasing the latter from its normal regulation
(Simon et al., 1997) (Figure 2).
In addition to the characteristic translocations and ring chromosomes, other
recurrent aberrations, such as deletions, chromosomal gains, double minutes, and
homogeneously staining regions, have also been described (Heim & Mitelman, 1995;
Sandberg, 1990). Similar to specific translocations, these other cytogenetic findings may
also reflect molecular genetic events with important pathogenetic roles, such as tumor
suppressor gene inactivation or oncogene amplification described below.
Figure 2. Schematic presentation of the formation of a ring chromosome
(17;22) containing amplified segments of both chromosomes and the
PDGFB/COL1A1 fusion gene. Below is the CGH profile for chromosome 22
from a dermatofibrosarcoma protuberans tumor (Study IV, case 15)
showing high-level amplification of chromosome 22.
Molecular genetic changes
Genes involved in tumorigenesis and tumor progression can be divided into those
directly controlling cellular proliferation, e.g., oncogenes and gatekeeper tumor
suppressor genes, and those controlling the rate of mutation, called caretaker tumor
suppressor genes.
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Oncogenes
Oncogenes are altered forms of normal cellular proto-oncogenes. An alteration in a
proto-oncogene causes constitutive activation or increased expression of the oncogene,
which leads to deregulated cell growth and proliferation. This activation may be caused
by a chromosomal translocation, a point mutation, an oncogenic virus, or by gene
amplification. Because oncogenes are dominant transforming genes, alteration of only
one of the two alleles is sufficient for their tumorigenic potential (Vogelstein & Kinzler,
1998).  Constant mutations in oncogenes in soft tissue sarcomas appear to be rare,
although mutations in the RAS gene family have been suggested to be involved in the
development of embryonal rhabdomyosarcoma (Stratton et al., 1989a). In
gastrointestinal stromal tumor (GIST), mutations of one growth-factor receptor, KIT,
appear to be recurrent (Hirota et al., 1998; Lux et al., 2000). These mutations lead to
aberrant tyrosine kinase activity. Based on the functional mechanism of the newly
synthesized tyrosine kinase inhibitor STI571, first applied in the treatment of CML,
Joensuu et al. applied STI571 in the treatment of GIST and reported recently on its
efficacy (Joensuu et al., 2001).
In addition to fusion gene formation and mutations, oncogenes may be activated
by gene amplification, which is commonly seen in soft tissue sarcomas. Gene
amplification results in gene activation by overexpression of one or more genes
contained in the amplicon.  Amplifications are often apparent cytogenetically, either as
double minutes, as ring chromosomes, or as homogeneously staining regions (Alitalo
et al., 1983; Brodeur et al., 1981; Cowell, 1982).
Tumor suppressor genes – gatekeepers
Gatekeeper tumor suppressor genes encode proteins that contribute to growth
regulation or to differentiation pathways. Instead of activation, functional repression of
both alleles of a tumor suppressor gene is needed for the tumorigenic potential. Thus,
tumor suppressor genes act recessively at cellular level. Tumor suppressor inactivation
may occur as a consequence of mutations or chromosomal deletions, of which the latter
may be large enough to be detected cytogenetically (Kinzler & Vogelstein, 1997).
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Knudson’s ”two-hit hypothesis” proposes that of the two inactivating events
necessary, the first one may be either germline (inherited) or somatic, and the second
one be always somatic (Knudson, 1971). Inherited aberrations in tumor suppressor
genes predispose to the hereditary cancer syndromes discussed below, which,
although rare, have been of great value for understanding the pathogenesis of various
types of sporadic cancers. Retinoblastoma (RB1) and tumor protein 53 (TP53) genes,
for example, both causing hereditary cancer susceptibility when inherited in a mutated
form, have proven to be of importance in the pathogenesis of a variety of sporadic
cancers, including soft tissue sarcomas (Mulligan et al., 1990; Reissmann et al., 1989;
Stratton et al., 1989b; Toguchida et al., 1992; Wunder et al., 1991). Many different
mechanisms for p53 inactivation appear in the literature. In soft tissue sarcomas, a
common p53 inactivation mechanism has been suggested to be the result of
amplification of the MDM2 oncogene, whose protein product binds to and functionally
inactivates p53 (Oliner et al., 1992).
Caretaker tumor suppressor genes - DNA repair genes
Like gatekeeper genes, DNA repair genes are targeted by inactivating mutations.
However, unlike the direct involvement of tumor suppressor genes in growth inhibition,
DNA repair genes play a less active role in regulating cell growth. Inactivation of both
alleles of a DNA repair gene leads to genetic instability, which indirectly promotes
growth by leading to an increased mutation rate (Kinzler & Vogelstein, 1997). Known
caretaker genes include nucleotide-excision-repair genes responsible for such
conditions as xeroderma pigmentosum, and mismatch-repair genes responsible for
hereditary nonpolyposis colon cancer, and probably the ATM gene responsible for ataxia
telangiectasia (Kinzler & Vogelstein, 1997). Recent evidence has implied that the two
breast cancer susceptibility genes known, BRCA1 and BRCA2, also possibly fall into
this category of tumor suppressor genes (Chen et al., 1998; Milner et al., 1997; Sharan
et al., 1997). Genetic instability in a tumor can be observed as defective alleles in
microsatellite markers, a phenomenon called microsatellite instability, which has been
reported in occasional studies on various soft tissue sarcomas, but the definitive role of
caretaker genes in sarcoma pathogenesis is unclear (Bedi et al., 1995; Risinger et al.,
1995; Suwa et al., 1999; Wooster et al., 1994).
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Inherited predisposition
A number of rare genetic diseases significantly increase the risk for certain
malignancies. The target genes in familial cancer syndromes usually represent tumor
suppressor genes, either gatekeeper or caretaker types, which are often aberrant in
sporadic tumors, as well.  As Knudson proposed in his "two-hit hypothesis," in familial
cancer cases, the first mutagenic event, or "hit," is present in the germline. The “second
hit” usually occurs somatically, inactivating the remaining allele of the susceptibility
gene. Since the likelihood of the somatic mutation, i.e., the second hit, is high, the
predisposition is clinically inherited as an autosomal dominant trait, although, at cellular
level a homozygous status is required. Few of the rare syndromes associated with
cancer susceptibility caused by mutations in caretaker genes, e.g., xeroderma
pigmentosum, are inherited recessively (Vogelstein & Kinzler, 1998).
Familial syndromes with an increased risk for soft tissue malignancies and other
cancers include Li-Fraumeni syndrome and familial adenomatous polyposis, which
represent typical cancer syndromes, with a high risk for breast cancer and sarcomas, for
example, in the former, and for gastrointestinal cancers and desmoid tumors in the latter
(Birch, 1994; Burt et al., 1995; Clark et al., 1999; Li & Fraumeni, 1982).
Neurofibromatosis type 1, Beckwith-Wiedemann syndrome, Costello syndrome, and
Werner syndrome mainly show manifestations other than malignancies but carry an
increased risk for malignancies which include certain soft tissue tumors (Hope &
Mulvihill, 1981; Huson et al., 1989; Kerr et al., 1998).
5.4. COMPARATIVE GENOMIC HYBRIDIZATION IN SOFT TISSUE SARCOMA
RESEARCH
Comparative genomic hybridization (CGH) (schematically presented in Figure 3) is
based on the comparative hybridization of tumor and normal DNA, each labeled with
different fluorochromes, on normal metaphase chromosomes. Differences in the
intensities of the two fluorochromes reveal alterations in the amount of DNA sequence in
the tumor genome (Kallioniemi et al., 1992). Thus, CGH indicates the genomic areas
with loss or gain of DNA in the tumor. Consequently, non-balanced translocations may
be seen by CGH as gains and losses of the chromosomal segment involved in the
translocation. Balanced translocations, which do not change the DNA copy number,
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cannot be detected by CGH. Recurrently noted losses suggest inactivation of a tumor
suppressor gene(s) in the lost genomic region, and recurrent gains or amplifications
indicate activation of an oncogene or of oncogenes within the amplicon (Kallioniemi et
al., 1992).
Figure 3. Schematic presentation of the CGH method. Equal amounts
of FITC-labeled tumor DNA and Texas Red–labeled normal control
DNA are hybridized to normal metaphase chromosomes. The
images are evaluated with a special image analysis program. The
signal intensities of the different fluorochromes are quantitated
along the single chromosomes. The over-and under-represented
DNA segments are quantified by computation of FITC/Texas Red
ratio images and average ratio profiles.
CGH overcomes the major disadvantages of conventional karyotypic analysis: the
requirement of fresh tumor tissue, as well as problems in analyzing complex
rearrangements. No mitotic cells are needed, which permits the analysis of tumors with
no established cellular proliferation.  The main disadvantages of the CGH method
include its incapability to discover balanced aberrations, as well as its interpretation
problems concerning certain genomic areas, and the requirement of a relatively large
amount of either amplified or lost DNA to allow each change to be detected. The
genomic areas exhibiting problems in copy number ratio profiling include the telomeric
Hybridization
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FITC/Texas Red Ratio
1.170.85
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and heterochromatic regions, which, especially as sole aberrations, cannot be
evaluated by CGH reliably (Kallioniemi et al., 1994). The sensitivity of CGH is dependent
on the proportion of tumor cells versus normal cells in the sample and the level of
amplification. An amplicon 1Mb in size may exceed the resolution limit, if it is very highly
amplified, and a loss of 10 to 12Mb can be detected, provided the proportion of aberrant
cells in the sample is sufficient (Bentz et al., 1998; Forozan et al., 1997). Recurrent DNA
copy number changes have been found useful as diagnostic and prognostic markers for
several cancer types, and the CGH method has even been used in localizing genes
responsible for inherited cancer syndromes (Hemminki et al., 1998; Isola et al., 1995;
Kainu et al., 2000; Moch et al., 1996; Suehiro et al., 2000). Since soft tissue sarcomas
frequently carry extremely complicated chromosomal aberrations, and the tumor tissue
is often available only as paraffin-embedded tissue sections, CGH is a highly useful
method for analyzing these tumors’ genetic aberrations. Consequently, since the
introduction of the CGH method in 1992 by Kallioniemi et al., a growing number of CGH
studies on different soft tissue tumor types have appeared, comprising today more than
10 different soft tissue sarcoma types and over 700 tumors (El-Rifai et al., 2000; Knuutila
et al., 1999; Knuutila et al., 1998; Mezzelani et al., 2000; Otano-Joos et al., 2000; Pandita
et al., 1999).
The most frequent copy number changes seen in soft tissue sarcomas include
gain of 1q21-q31 which is at least partly present in approximately 25% of the cases
analyzed by CGH, followed by gains of 8q and 12q13-q15, at least partly present in
approximately 23% and 20%, respectively. Losses are much rarer than gains; the most
frequent loss by far is seen at 13q21, present in 22% of soft tissue sarcomas. All of
these recurrent changes have been reported in most soft tissue sarcoma types studied
by CGH.  Gain or high-level amplification of 1q21-q31 is most frequent in LMS
(approximately 50%) and liposarcoma (40%); gain or high-level amplification of 8q in
embryonal rhabdomyosarcoma (64%); and gain or high-level amplification of 12q13-q15
in both embryonal and alveolar rhabdomyosarcoma (52% and 55%) as well as
liposarcoma (47%). Loss of 13q21 is most frequently seen in LMS, being present in
approximately 53% of cases. The frequencies have been calculated from nearly 70
original articles, most of them reviewed by Knuutila et al. (El-Rifai et al., 2000; Knuutila et
al., 1999; Knuutila et al., 1998; Mezzelani et al., 2000; Otano-Joos et al., 2000; Pandita et
al., 1999). The reviews are also available at http://www.helsinki.fi/~lgl_www/CMG.html.
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Several recurrent DNA copy number changes have been shown to be of clinical
relevance in soft tissue tumor evaluation. In the differential diagnosis of lipoma from
liposarcoma, for example, the over-representation of DNA copy number gains at
chromosomes 12q and 1q in liposarcomas but not in lipomas can be extremely helpful,
especially concerning large and deep-seated lipomas and lipoma-like liposarcomas
(Szymanska et al., 1997). Patterns of DNA copy number changes which differ between
benign and malignant GISTs have, for their part, proven useful in the context of
diagnostic and prognostic categorization. Significant differences in changes in several
specific chromosomal areas as well as differences in the total number of changes have
been detected between benign GISTs, malignant primary GISTs, and metastases (El-
Rifai et al., 2000; El-Rifai et al., 1998a; Sarlomo-Rikala et al., 1998). CGH may also be
relevant in predicting the prognosis of MFH, since gain of 7q32 is significantly correlated
witha worse outcome for the patient(Larramendy et al., 1997).
Some of the recurrent DNA copy number gains, including gains of 12q, 11q13,
and 17p, have been further studied by molecular genetic methods and been shown to
be of complex structure. The 12q13-q15 region, for example, harbors many proto-
oncogenes, including MDM2, CDK4, SAS, CHOP10/DDIT3, and GLI. In an amplicon,
separate regions, e.g., the one carrying the MDM2 gene in one segment, and the one
carrying the CDK4 and SAS genes in another segment, are co-amplified, whereas the
intervening sequences show none or reduced amplification, and even losses of DNA
sequences are apparent (Berner et al., 1996; Gaudray et al., 1992; Wolf et al., 1997a;
Wolf et al., 1997b; Wolf et al., 1999). In most instances, however, the target genes and
their exact roles in tumorigenesis and tumor progression are yet to be revealed. Since by
CGH only a somewhat approximate evaluation of copy number changes is possible,
CGH serves mainly as a tool for identifying chromosomal areas of interest to allow
further studies by other methods. Recent applications of array technology have enabled
the characterization of either copy number changes or gene expression profiling of tens
of thousands of single genes or sequences in a single experiment (methods reviewed
in Nature Genetics supplement issue for vol. 21, 1999). The identification of genetic
mechanisms underlying malignant processes will ultimately lead to development of new
specific drugs, as already used for CML, and preliminarily also for GIST (Druker et al.,
2001a; Druker et al., 2001b; Joensuu et al., 2001).
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6. AIMS OF THE STUDY
This study was directed at characterizing genetic alterations in rare soft tissue sarcomas
and Ewing tumors. The specific aims were:
To identify DNA copy number changes in alveolar soft part sarcoma, low-grade
fibromyxoid sarcoma, Kaposi's sarcoma, dermatofibrosarcoma protuberans, and Ewing
tumors, the first three representing tumors with no previously characterized recurrent
DNA copy number alterations.
If any recurrent aberrations of special interest were found, to study these further with
other methods.
By comparing the copy number changes between typical and fibrosarcomatously
transformed dermatofibrosarcoma protuberans, to study whether certain DNA copy
number alterations are associated with tumor progression.
To study whether recurrent DNA copy number changes in Ewing tumors have prognostic
value.
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7. MATERIALS AND METHODS
7.1. MATERIALS
For Study I, 14 ASPS tumor samples from 13 patients were obtained from the Armed
Forces Institute of Pathology (AFIP), Washington, DC. The diagnoses were made
histologically and further confirmed by immunohistochemical evaluation. The patients
were from 9 to 67 years of age (average 25 years), six of them females and eight males.
The clinical characteristics of the patients are shown in Table 2.
Study II comprised 11 cases of histologically and immunohistochemically
evaluated LGFMS tumors from the Soft Tissue Registry of AFIP. These tumors had
occurred in six men and five women, average age 43. Nine were primary tumors in the
extremities, and two were pulmonary metastases. The clinical data are shown in Table
2.
Table 2.  Clinical characteristics of ASPS and LGFMS patients
Case Age/
Sex
Tumor Location Tumor Size
Alveolar soft part sarcoma
I-1 9/M Abdominal wall, subcutis 5 cm
I-2 34/M Scalp 3 cm
I-3 26/F Thigh unknown
I-4 23/F Thigh 10.5 cm
I-5a
1 26/M Thigh, deep 6 cm
I-5b
1  "         "    "
I-6 19/M Thigh 4.5 cm
I-7 17/F Upper arm 3 cm
I-8 40/M Back, intramuscular 5 cm
I-9 18/M Scalp, subcutis unknown
I-10 15/F Shoulder 2.5 cm
I-11 67/M Spermatic cord unknown
I-12 9/F Thigh 2.3 cm
I-13 28/F Paravaginal tissue 6 cm
Low-grade fibromyxoid sarcoma
II-1 42/M Leg “large”, > 10 cm
II-2 79/F Buttock “large”, > 10 cm
II-3 23/M Leg 14 x 7 x 5 cm
II-4 52/M Brachial plexus region 11 x 8 x 5 cm
II-5 26/F Thigh 10.5 x 8.5 x 4.5 cm
II-6 50/M Upper arm 5 x 4.5 x 2 cm
II-7 54/F Inguinal region 5 x 3.5 x 3 cm
II-8 27/F Forearm 5 x 3.5 x 2.5 cm
II-9 29/M Thigh 5 x 3.5 x 2.5 cm
II-10 50/F Pulmonary metastasis variable sizes
II-11 39/M Pulmonary metastasis Variable sizes, from 2.5 to 5 cm
1 
5a and 5b represent two different samples from the same tumor
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Study III included histologically and immunohistochemically diagnosed Kaposi's
sarcoma samples from 12 patients. Nine of these patients were treated at Helsinki
University Central Hospital, Departments of Dermatology (four patients), Surgery (two),
Otology (two), and Medicine (one). Seven of the Finnish patients were males; two of
them had HIV-infections. Both female patients were HIV-negative, one of them was a
Somalian immigrant diagnosed with lupus erythematosus disseminatus (LED) -
associated nephropathy.  Three samples were obtained from the Soft Tissue Registry of
AFIP, from patients who were HIV-positive American males.  Clinical data for all Kaposi’s
sarcoma patients are shown in Table 3.
Table 3. Clinical data for Kaposi's sarcoma patients
Case Age/Sex Site1 Additional
diagnosis2
Ethnic origin
III-1 29/F Skin, arm LED Somalian
III-2 29/M Gingiva HIV Finnish
III-3 69/M Skin, ankle - Finnish
III-4 33/M Subcutis, neck HIV Finnish
III-5 73/F Skin, chin - Finnish
III-6 32/M Scrotum AIDS American
III-7 50/M Tongue AIDS Finnish
III-8 35/M Jejunum AIDS American
III-9 77/M Skin, leg - Finnish
III-10 76/M Skin, foot - Finnish
III-11 70/F Skin, leg - Finnish
III-12 61/M Skin, toe AIDS American
1 site of tumor from which samples were taken (most patients presented with
multifocal disease)
2 LED, lupus erythematosus disseminatus; HIV, human immunodeficiency virus
infection
For Study IV, 21 samples from 19 DFSP tumors were obtained from the Soft
Tissue Registry of AFIP. Nine of the tumors were classical DFSPs, and ten presented
with fibrosarcomatous changes. From two FS-DFSP cases, both typical DFSP areas as
well as fibrosarcomatous areas were included separately. The diagnosis was made by
histological and immunohistochemical procedures. Clinical data for the patients are
shown in Table 4.
Study V included 28 Ewing tumor samples: 16 samples were from Helsinki
University Central Hospital, five from the Rizzoli Institute, Bologna, Italy, and five from the
Scandinavian Sarcoma Group; 11 cases had been published previously (Armengol et
al., 1997). Of these tumors, 24 were typical Ewing’s sarcomas, one was atypical, and
three were primitive neuroectodermal tumors; 16 were soft tissue tumors, and 12 were
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bone tumors. All samples were obtained from primary tumors prior to any treatment.
Clinical data are shown in Table 5.
Table 4. Clinical data for DFSP patients
Case Age/Sex Site Tumor size DFSP/ FS-DFSP
IV 1a 52/F Vulvar area 5.0 cm DFSP
IV 1b   "       "     " FS-DFSP
IV 2a 45/M Abdominal wall 15.0 cm DFSP
IV 2b   "       "     " FS-DFSP
IV 3 45/M Back 6.5 cm DFSP
IV 4 14/M Toe unknown DFSP
IV 5 36/M Deltoid muscle 1.3 cm DFSP
IV 6 65/M Supraclavic area 7 cm DFSP
IV 7 47/M Groin 4.0 cm DFSP
IV 8 55/M Chest wall 1.5 cm DFSP
IV 9 39/M Toe 1.6 cm DFSP
IV 10 16/M Back unknown DFSP
IV 11 49/M Back unknown DFSP
IV 12 24/F Ant. chest wall unknown FS-DFSP
IV 13 20/F Suprascapular area unknown FS-DFSP
IV 14 59/M Buttock 9.0 cm FS-DFSP
IV 15 42/M Chest wall 4.1 cm FS-DFSP
IV 16 36/M Shoulder 4.0 cm FS-DFSP
IV 17 37/F Scapula 2.7 cm FS-DFSP
IV 18 41/F Inguinal region unknown FS-DFSP
IV 19 72/F Thigh 9.0 cm FS-DFSP
Table 5. Clinical data for Ewing tumor patients
Case Age/Sex Site/ bone vs. soft tissue Tumor size Stage at dg3
V-1 24/F Knee region/soft tissue 18x7x6 cm M1
V-2 33/M Calf/soft tissue 10x20 cm M1
V-3 18/F Shoulder blade region/soft tissue 9x11x3 cm M0
V-4 27/F Femur/bone 10x15 cm M0
V-51 36/F Ankle/soft tissue 10x7x3 cm M0
V-6 19/F Pelvis/bone 7x5 cm M0
V-7 33/F Subcutis, thigh/soft tissue 7x3 cm M0
V-8 36/F Buttock/soft tissue 15x8x10 cm M0
V-9 12/F Rib/bone 4.4x4.4 cm M0
V-10 2/M Ulna/bone 6.5 cm M0
V-11 26/F Rib/bone 6 cm M0
V-12 18/M Thigh/soft tissue 20x10x5 cm M0
V-13 21/F Forearm/soft tissue 8x7x6 cm M1
V-14 30/M Calf/soft tissue unknown M0
V-15 49/F Thigh/soft tissue 10x8x5 cm M1
V-162 26/F Back/soft tissue 20x10x7 cm M0
V-17 17/M Calf/soft tissue 4x3 cm M0
V-18 20/F Knee region/soft tissue 8x12 cm M1
V-19 29/F Retroperitoneum/soft tissue 7 cm M0
V-20 28/M Tibia/bone 6x4 cm M1
V-21 8/M Femur/bone 6x6 cm M0
V-22 32/F Spine/soft tissue 6x3 cm M1
V-23 8/F Femur/bone 10x8 cm M0
V-24 27/F Sacrum/bone 9x6 cm M1
V-252 28/M Hand/soft tissue 1.5 cm M0
V-262 18/M Tibia/bone 15x6 cm M0
V-27 24/F Sacrum/bone 10x12 cm M0
V-28 2/F Radius/bone 3.5x9 cm M0
1 atypical Ewing’s sarcoma; 2primitive neuroectodermal tumor; 3MO=no metastases at
diagnosis, M1= metastases at diagnosis
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7.2. METHODS
Comparative genomic hybridization (Studies I-V)
Representative areas of the purest available tumor tissue were chosen for the studies.
DNA was extracted from paraffin sections by a salting-out procedure (Miller et al., 1988).
The comparative genomic hybridization analyses in Studies I to IV were performed as
described in El-Rifai et al., 1997, and those in Study V as described in Armengol et al.,
1997. Briefly, in Studies I to IV, tumor DNA was labeled by nick-translation with a mixture
of FITC-dCTP and FITC-dUTP (1:1; DuPont, Boston, MA, USA) and normal reference
DNA with a mixture of Texas Red-dCTP and Texas Red-dUTP (1:1; DuPont). In Study V,
FITC-12-dUTP (DuPont) and Texas Red-dUTP (DuPont) were used accordingly. The
nick-translation reaction was optimized to produce DNA fragments of 600 to 2000 bp in
length.  Equal amounts (800ng) of labeled tumor and control DNA together with 20µg of
unlabeled human Cot-1 DNA (Gibco BRL, Paisley, UK) were hybridized to normal
metaphase spreads. After a two- to three-day hybridization, the slides were washed,
then counterstained with DAPI (Sigma, St Louis, MO, USA), and finally mounted with
antifading medium (Vectashield™, Vector Laboratories, Burlingame, CA, USA).
The analysis of the hybridizations was performed with an Olympus fluorescence
microscope and the ISIS digital image analysis system (Metasystems GmbH,
Altlussheim, Germany). Three-color images of five to nine good-quality metaphases
were taken of each sample. The signal intensity ratios of green (FITC) to red (Texas
Red) along the chromosomes were calculated. Chromosomal regions were interpreted
as over-represented when the ratio exceeded 1.17 (gains), and under-represented when
the ratio fell below 0.85 (losses). A ratio over 1.5 served as the cut-off value for high-level
amplifications. Results were expressed with a 99% confidence interval.
Polymerase chain reaction (Study III)
HHV-8-specific PCR was used to establish the presence of the virus DNA in six
Kaposi’s sarcoma samples. The forward and reverse primers 5'-
ggagggcacgctagcttcagtg and 5'-tcctcactccaatcccaatgc, respectively, were used to amplify
the K12 (or kaposin) open reading frame of HHV-8. Ten epitheloid sarcoma samples,
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one DFSP sample, and water served as controls. The PCR cycles were: 94°C for 10 min
to activate the enzyme, then 30 times at 94°C for 15 sec, 55°C for 30 sec, and 72°C for
40 sec, then 72°C for 5 min in a reaction mixture containing 200 µM of each dNTP, 0.6
µM of each primer, and 2.5 units of Ampli Taq Gold polymerase in the buffer supplied by
the manufacturer (Perkin Elmer Applied Biosystems, Foster City, CA, USA).
The amplified products were separated by gel electrophoresis, transferred to nylon
membrane, and hybridized to a digoxigenin-labeled probe. The probe was made by
incorporation of DIG-11-dUTP (Boehringer-Mannheim, Mannheim, Germany) into the
synthesized DNA strands by PCR, using the same primers and conditions as above.
Interphase fluorescence in situ hybridization (Study III)
Two yeast artificial chromosome (YAC) clones, 55G7 and 214D11, served as probes in
study of the amplification of the genes FGF4 and INT2 (alias FGF3) in Kaposi’s
sarcoma. Both YAC clones covered the region of the closely located FGF4 and INT2
genes on chromosome 11q13 (Courseaux A, 1996). The clones were obtained from the
Resource Center/Primary Database of the German Human Genome Project (RZPD,
Berlin-Charlottenburg, Germany). YAC 950, which hybridizes to 11p16, was used as a
control probe. The biotin-14-dATP-labeled probes were hybridized on nuclei extracted
from paraffin sections and visualized with FITC. The probes, when hybridized on normal
metaphase chromosomes, gave specific hybridization signals at the expected locations.
The nuclei preparations were deparaffinized at 65°C for 15 minutes, followed by
xylene treatment (3 x 5 min) at room temperature, and then dehydrated in a descending
alcohol series. Approximately 1 µg of the probes was labeled with biotin-14-dATP, and
precipitated together with 50 µg of Cot-1 DNA (Gibco BRL), 50 µg of herring sperm DNA
(Boehringer Mannheim), 1/10 volume of 3 M sodium acetate, and 14 volumes of
absolute ethanol.
Before hybridization, the slides were dipped into 1M sodium thiocyanate at 70°C
for 15 min, 0.05 N HCl at 37°C for 10 min, and 0.05 N HCl containing 5 mg/ml pepsin at
37°C for 20 min. The slides were denatured at 75°C for 5 minutes according to standard
methods. The hybridization was performed in a moist chamber at 37°C for two to three
days.
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After hybridization, the slides were washed once in 2 x SSC and twice in 0.1 x SSC
at 45°C, for 5 minutes each. The biotinylated probes were detected by avidin-TRITC
(1:500, Vector) that was amplified with biotinylated anti-avidin (1:100, Vector) and avidin-
TRITC (1:500) with incubations of 40, 45, and 40 minutes, respectively, at 37°C. The
counterstaining was performed with 4’,6-diamindino-2-phenylindole (DAPI, 2 µg/ml) for
10 minutes.
All probes showed two signals in over 73% of the cells when hybridized on nuclei
extracted from paraffin-embedded reactive lymphatic tissue, which served as a control
target.
Immunostaining with anti-FGF4 and INT2 antibodies (Study III)
Nine Kaposi’s sarcoma tumors were subjected to immunostaining to study whether the
amplified FGF4 and INT2 genes were expressed in these tumors. Monoclonal anti-
human FGF-4 (Sigma) and anti-mouse INT-2 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) were used as antibodies at dilutions of 1:1000 and 1:50, respectively.
Formalin-fixed and paraffin-embedded tumor sections were stained by the avidin-biotin
complex immunoperoxidase method with an Elite ABC kit (Vectain, Vector). In each
section, non-neoplastic tissue around the tumor tissue served as a control.
Statistical analyses (Studies IV and V)
In Study IV, the total number of CGH changes and the number of 1p34-pter were tested
for differences between the DFSP group and the FS-DFSP group by the t-test and Fisher
Exact Probability Test, respectively.
In Study V, the aberrations seen in at least three Ewing tumors by CGH (gain or
high-level amplification of chromosomes 8, 1q21-q22, 7q, 6p21.1-pter, and 12; and loss
of chromosome 16q) and the total number of aberrations per tumor were tested for
prognostic significance. Distant disease-free survival (DDFS) and overall survival rates
were tested by the Kaplan-Meier method. Associations of copy number changes, tumor
size (largest diameter over 8 cm versus 8 cm or less), and tumor location (central versus
extremities) with overall survival, DDFS, and local recurrence were tested with the log-
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rank test. The statistical significance of the total number of aberrations per tumor was
calculated with Cox regression analysis.
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8. RESULTS
8.1. COPY NUMBER ALTERATIONS IN ALVEOLAR SOFT PART SARCOMA, LOW-
GRADE FIBROMYXOID SARCOMA, KAPOSI'S SARCOMA, DERMATOFIBRO-
SARCOMA PROTUBERANS, AND EWING TUMORS (STUDIES I-V)
The CGH results are summarized in Table 6 and Figure 4. Of 86 samples, 84 (81/83
tumors) could be successfully studied by CGH; hybridizations of two of the 12 Kaposi’s
sarcomas were repeatedly unsuccessful. Of these samples, 61 (58/81 tumors) showed
DNA copy number changes (73%).  Gains were much more common than losses; 155
single gains were detected, of which 30 were at least partly of high level, compared to
only 54 single losses. The most frequent gains or high-level amplifications were those
of chromosomes 17q21-qter (24 samples), 22pter-q13 (18), 8q (18, of which 13 were
from soft tissue tumors), and 1q21-q22 (13, of which 10 were from soft tissue tumors).
The most frequent loss was that of 13q21-q22, seen in six cases. Each of the
chromosomes (except for the Y chromosome, which is excluded from the CGH analysis)
was affected at least once.
Table 6. DNA copy number changes in ASPS, LGFMS, Kaposi’s sarcoma,
typical DFSP, FS-DFSP, and Ewing tumors
Case DNA copy number changes1
I ASPS
I-2 +1q, +12q, -18
I-5a -1p13-p31, -3, +8q, -9p13-pter, +16p, +18p11.2
I-5b -1p, -3, +8q, +16p,-16q
I-9 +Xp11-pter, -12p, +12q, -21
I-11 +1q, +8q, +16
II LGFMS
II-1 +1q21-q31, +4cen-q22, -4q22-qter, -5q13-q33, -7p, -9p21-pter, -13, -18p,  +20q
II-2 -3p13-pter, -3q24-qter, -9p13-pter, -13q14-qter, -14q21-pter, +17q, -21q21-pter
II-3 -6q, -13
II-4 -1q41-qter, -3p12-p22, -13q22-pter, -22q12-qter
II-5 +X, -13, +16p
II-6 +20q11-qter
II-7 -2q34-pter, -4, -7q21-qter, -13q21-qter, +19
II-10 +7q22-q35, +8
II-11 +7q
III Kaposi’s sarcoma
III-1 +11q13
III-2 +11q13
III-3 +11q13, +22
III-4 +11q13, +16p
III-5 -6q24-qter, +8q, -10, +16p
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Table 6. continued
IV DFSP - typical
IV-1a +5, +8, +11, +12p12-pter, +12q24.1-qter, ++17q21-qter, +20, ++22
IV-2a +17cen-q21, ++17q21-qter
IV-3 +5, -8p12-pter, +17cen-q21, ++17q21-qter, +21q21-qter, +22pter-q13
IV-4 +1, +7, +17q21-qter, +22pter-q13
IV-5 -3q13-q26, +4, +12, -14q21-q32, ++17q21-qter, ++18, +22
IV-6 +5cen-q33, ++17q21-qter
IV-7 +17q21-qter, +22
IV-8 -4p14-pter, ++17q21-qter, +22
IV-9 -6q14-qter, +17cen-q21, ++17q21-qter, ++22pter-q13, +22q13-qter
IV-10 +1q21-q24, +17pter-q21, ++17q21-qter, ++22pter-q13, +22q13-qter
IV-11 +17cen-q21, ++17q21-qter, +22pter-q13
DFSP  with fibrosarcomatous change
IV-1b ++5, +8, +11, +12p, +12q23-qter, +17pter-q21, ++17q21-qter, +20p, ++20q,
++21, ++22
IV-2b -6q16-qter, +17cen-q21, ++17q21-qter, +22
IV-12 -X, +1, +5q12-q14, +5q23-q34, +6p21.1-pter, +15q21-q25, +17cen-q21,
++17q21-qter
IV-13 -X, ++17q21-qter, +22pter-q13
IV-14 +17q21-qter
IV-15 +1p34-pter, -3cen-q26, +5, +8, -9pter-q22, +9q34-qter, ++17q21-qter,
+20q13-qter, +21, ++22
IV-16 +1,+5p13-qter, +16, ++17q21-qter, +18, +21, +22pter-q13
IV-17 +1pter-q31, +7, +12, +13, +17cen-q21, ++17q21-qter
IV-18 +12, +17q21-q22, ++17q22-qter, +22
IV-19 +17pter-q21, ++17q21-qter, +22
V Ewing tumors
V-1 +1q21-22, +8, +12, +14q, +21q
V-4 +4q27-q33, +7q, -11q21-q25, -16
V-5 -3q
V-6 -1p13-p36, +1q21-q31, -9p
V-7 +16q
V-8 +6, +8
V-10 +8
V-11 +4, +8, +12, +14q13-q32
V-12 +7, +8, +16p, +20q
V-13 ++6p, +18p, ++19
V-15 +18p11-qter
V-16 +6p21.1-pter
V-17 +7, +8
V-18 +2, +8, +9, +17
V-19 -7
V-20 +1q, -4, +8, -11
V-21 +X
V-22 ++1q, -16q, +16p, +17, +22
V-24 +7, +8
V-26 +7
V-27 +1q, +8, +12, -16q
1 
gains of DNA sequences are marked with +, and losses with -. Only cases with
aberrations are shown.
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Figure 4. DNA copy number gains and losses for 81 successfully studied
tumors. Losses are on the left side of the chromosomes and gains on the
right; high-level amplifications as bold lines.
ASPS, alveolar soft part sarcoma (14 samples from 13 tumors); LGFMS,
low-grade fibromyxoid sarcoma (11 tumors); Kaposi's sarcoma (10
successfully hybridized tumors); DFSP and FS-DFSP, typical and
fibrosarcomatously transformed dermatofibrosarcoma protuberans (11
and 10 samples, respectively, from a total of 19 tumors); ET-soft, Ewing
tumor of soft tissue (16 tumors); ET-bone, Ewing tumor of bone (12
tumors).
a and b, different samples from same tumors.
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Of these most recurrent changes, gain or high-level amplification of 1q21-q22
was present in four and 8q in all five types of tumors. The 1q21-q22 gain was present in
two ASPS cases, five DFSP cases (two of the typical and three of the fibrosarcomatous
type), one LGFMS case, and five Ewing tumors (two soft tissue and three bone tumors).
Gain of 8q was seen in two ASPS samples (from the same tumor), one LGFMS, one
Kaposi’s sarcoma, three DFSP samples (two of which represented fibrosarcomatous
and typical areas of one single tumor), and ten Ewing tumors (five soft tissue and five
bone tumors). The other two gains or high-level amplifications, 17q21-qter and 22pter-
q13, were both seen in three different types of tumors: Gain of 17q21-qter was present in
one LGFMS, all 19 DFSP tumors (21 samples), and two extraskeletal Ewing tumors.
Gain or high-level amplification of 22pter-q13 was present in one Kaposi’s sarcoma, 15
DFSP tumors (16 samples), and one extraskeletal Ewing tumor. The most recurrent
loss, 13q21-q22, was seen only in LGFMS. The only change in all five types of tumors
was gain of 16p, present in two ASPS tumors (three samples), one LGFMS, two
Kaposi’s sarcomas, one DFSP, and two extraskeletal Ewing tumors.
Proportionally, in distinct tumor types, the most recurrent changes included those
already mentioned in DFSP, namely gain or high-level amplification of 17q21-qter,
present in 100%, and gain or high-level amplification of 22pter-q13, present in 79% of
the DFSP tumors, as well as loss of 13q21-q22 in LGFMS, appearing in 6 of 11 or 55%
of the cases.
8.2. HUMAN HERPESVIRUS 8-SPECIFIC SEQUENCES IN KAPOSI’S SARCOMA
(STUDY III)
All six tumors from which DNA was available for the PCR study were positive for the K12
(kaposin) open reading frame of HHV-8, yielding an expected 222 bp fragment in gel
electrophoresis, whereas all the negative controls were negative.
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8.3. THE ROLE OF TWO CANDIDATE GENES AT CHROMOSOME 11q13 IN KAPOSI’S
SARCOMA (STUDY III)
Interphase fluorescence in situ hybridization and immunohistochemistry
As shown in Table 7, seven of the 12 tumors were studied by interphase fluorescence in
situ hybridization (FISH) with both YAC probes, 55G7 and 214D11, and nine of the
tumors were evaluated immunohistochemically with anti-FGF4 and anti-INT2. One of the
hybridizations with 214D11 was unsuccessful. Hybridization of the same tumor with
55G7 gave two signals. This tumor showed weak FGF4 immunoreactivity, and no INT2
reactivity. Two signals with both probes were seen in one case with strong positivity for
FGF4 and focal positivity for INT2. All the other tumors gave more than two FISH signals,
the mean ranging from three to four signals. These tumors showed variable
immunoreactivity; one case was negative for both FGF4 and INT2, two tumors were
positive for both, and one tumor was positive for FGF4 but negative for INT2. One of the
tumors with more than two FISH signals was not evaluated immunohistochemically
because no sample was available. Two tumors available only for immunohistochemistry
were both positive for FGF4 and both negative for INT2.
Table 7. Summary of CGH, FISH, immunohistochemical staining, and HHV-8-specific
PCR results for 12 Kaposi’s sarcoma cases
Case Copy number
changes1
Number of FISH-signals2 Immunoreactivity
of tumor cells
HHV-8
PCR
YAC 55G7 YAC 214D11 FGF4 INT2
III-1 +11q13 3(2-5) 3(2-5) - - na
III-2 +11q13 na na + - +
III-3 +11q13, +22 3(2-5) 3(2-6) na na na
III-4 +11q13, +16p na na + - na
III-5 -6q24-qter, +8q, -10, +16p 3(2-5) 3(2-5) ++ ++ na
III-6 nr 4(2-5) 4(2-6) + + na
III-7 nr 4(2-6) 3(2-6) + - +
III-8 none 2 2 ++ + +
III-9 none na na ++ - +
III-10 none na na na na +
III-11 none na na na na na
III-12 none 2 nr + - +
1 
nr, unsuccessful hybridization
2 
na, no sample available
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8.4. COMPARISON OF DNA COPY NUMBER CHANGES BETWEEN TYPICAL AND
FIBROSARCOMATOUSLY TRANSFORMED DERMATOFIBROSARCOMA
PROTUBERANS (STUDY IV)
DNA copy number changes were present in each sample of both the DFSP and FS-
DFSP groups. Altogether 47 copy number changes were observed in the 11 DFSP
samples (mean 4.3 changes per sample) and 57 changes in the 10 FS-DFSP samples
(mean 5.7 per sample). The number of changes ranged from 2 to 8 in the DFSP group,
and from 1 to 11 in the FS-DFSP group. High-level amplifications were observed in 13
DFSPs and 14 FS-DFSPs.
The most recurrent change was gain or high-level amplification of 17q21-qter,
which was present in all samples in both groups. This was followed by gain or high-
level amplification of 22pter-q13, present in nine (82%) and seven (70%) of the DFSP
and FS-DFSP samples, respectively. The third most common change was seen at 5q, at
which two minimal overlapping areas (5q12-q14 and 5q23-34) were gained or amplified
in three DFSP and four FS-DFSP samples (27% and 40%, respectively).
Comparison of the changes in the DFSP and FS-DFSP groups revealed no
statistically significant differences: the clearest differences occurred in the total number
of changes (P=0.24), and gain of 1p34-pter, which was present in one DFSP sample
and in four FS-DFSP samples (P=0.15).
8.5. PROGNOSTIC SIGNIFICANCE OF DNA COPY NUMBER CHANGES IN EWING
TUMORS (STUDY V)
The total number of aberrations detected by CGH per tumor showed no statistically
significant correlations with the prognostic parameters (P=0.08 for DDFS and 0.13 for
overall survival). Among the most frequent aberrations tested for prognostic impact,
certain associations were found, none of which was, however, statistically significant:
the most frequent aberration, gain of chromosome 8 (present in 36%), was associated
with trends towards worse DDFS (P=0.16) and worse overall survival (P=0.39). Gain or
high-level amplification of 1q21-q22 (present in 18%) showed similar associations
(P=0.30 and 0.45, respectively). The DDFS and overall survival of patients with gain of 7q
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(present in 18%) were slightly better than of those without 7q gain (80% versus 51%,
P=0.30 for DDFS; and 75% vs. 53%, P=0.45).
Gain or high-level amplification of chromosome 6p21.1-pter (present in 11% of
the tumors) was associated with poor prognosis: none of the patients with this
aberration survived for 5 years, whereas the 5-year overall survival of the patients without
this aberration was 64% (P=0.004). Similarly, the 5-year DDFS among the patients with
and without this imbalance was 0% and 63%, respectively (P=0.04). Gain of
chromosome 12 (present in 11%) was associated with a trend towards worse DDFS
(P=0.36), but no association was detectable between this gain and overall survival
(P=0.67). The most frequent loss at 16q (appearing in 11%) showed no correlation with
any of the prognostic parameters.
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9. DISCUSSION
9.1. EXTRACTING INFORMATION FROM SOFT TISSUE SARCOMAS BY COMPARATIVE
GENOMIC HYBRIDIZATION
CGH overcomes many problems associated with conventional cytogenetic analysis.
First, the requirement of only DNA instead of viable cells allows the use of archival tumor
material, which is especially important when studying rare tumors. Even in the presence
of fresh tumor samples, cellular proliferation is often difficult to establish for banding
analysis. Second, by CGH the overview of even a very complex karyotype can easily be
achieved. Although CGH is an efficient method for screening DNA copy number
changes, it cannot, however, be used to analyze amplification of single genes, not to
mention gene expression. Thus, once the interesting copy number alterations have
been found, the genes of interest must be further studied by other molecular genetic
methods. In addition to revealing chromosomal segments carrying genes with potential
importance in tumorigenesis and tumor progression, DNA copy number changes may
be useful in clinical assessment, such as differential diagnostics, tumor categorization
and prognostic evaluation.
In this work, CGH has been applied in the study of archival samples of very rare
soft tissue sarcomas and Ewing tumors. No satisfactory number of fresh tumor
samples of this nature could have been obtainable for a search for aberrations by
conventional methods. DNA copy number changes of the rare ASPS, Kaposi’s sarcoma,
and LGFMS tumors were reported during these studies for the first time, and new
information on copy number changes in DFSP as well as in Ewing tumors were added
to those previously described. The frequencies of the most common changes seen in
the present study are compared in Table 8 to previously described frequencies in other
soft tissue sarcomas.
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Table 8. Frequency of recurrent copy number changes in present and previous
studies
Number of tumors with the copy number change (%)1
G a i n  o r  h i g h - l e v e l  a m p l i f i c a t i o n L o s s 
17q21-qter 22pter-q13  8q 1q21-q22 13q21-q22
Studies I-V (69 tumors)2 22 (31%) 17 (24%) 11 (15%) 10 (14%) 6 (8%)
Other studies (517 tumors)3 62 (12%) 36 (7%) 99 (19%) 106 (21%) 110 (21%)
Malignant fibrous histiocytoma 
(155 tumors)
15 (10%) 17 (11%) 18 (12%) 32 (21%) 35 (23%)
Leiomyosarcoma (72) 12 (17%) 11 (15%) 21 (29%) 27 (38%) 38 (53%)
Synovial sarcoma (76) 8 (11%) 1 (1%) 10 (13%) 5 (7%) 11 (14%)
Embryonal rhabdomyosarcoma
(33)
4 (12%) 2 (6%) 19 (58%) 4 (12%) 1 (3%)
Alveolar rhabdomyosarcoma
(55)
9 (16%) 2 (4%) 10 (18%) 13 (24%) 5 (9%)
Liposarcoma (55) 4 (7%) 3 (5%) 11 (20%) 20 (36%) 6 (11%)
Gastrointestinal stromal tumor
(71)
10 (14%) 0 10 (14%) 5 (7%) 14 (20%)
1 Tumors with the change covering more than half of the region mentioned
2 Comprising 13 alveolar soft tissue sarcomas, 11 low-grade fibromyxoid sarcomas, 10
Kaposi’s sarcomas, 19 dermatofibrosarcoma protuberanses, 16 soft tissue Ewing tumors
3 References: (El-Rifai et al., 2000; Knuutila et al., 1999; Knuutila et al., 1998; Otano-Joos et
al., 2000; Pandita et al., 1999)
9.2. WHAT DO COPY NUMBER CHANGES TELL ABOUT THE TUMORS?
No specific copy number changes in alveolar soft part sarcoma
The molecular cytogenetic background of ASPS was discovered after Study I was
published. A specific translocation der(17)t(X;17)(p11;q25) was identified, similar to
many sarcoma types (Joyama et al., 1999). This rearrangement brings extra
chromosomal material from Xp11-pter to chromosome 17q25, and leads to a novel
fusion gene between TFE3 transcription factor at Xp11.2 and a novel gene, ASPL, at
17q25 (Ladanyi et al., 2001). Interestingly, one of the ASPS tumors in Study I showed
gain of Xp with the starting point coinciding with band p11. This fits well with the non-
reciprocal nature of the translocation with excess material from Xp in at least some of
the cases (Joyama et al., 1999). Compared to other specific translocations, typically of
the balanced type, one could speculate that the excess chromosomal material
introduced by the unbalanced situation might itself carry some pathogenetic importance
in addition to the fusion gene formation.
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Copy number aberrations present in two ASPS tumors each included gains of 1q,
8q, 12q, and 16p. The first three represent the most frequent aberrations in soft tissue
sarcomas in general, and are unspecific as to tumor types. The high prevalence of these
changes in different sarcoma subtypes may suggest that the same oncogenes act in the
progression of both the more common as well as the very rare sarcoma types. Gain of
16p has most frequently been reported in LMS (approximately 26%). Considering the
smooth muscle origin of LMS, it is of interest that for ASPS, skeletal muscle
differentiation of the tumor cells has been suggested. The 16p gain has, however, been
reported in several other sarcomas as well, and thus cannot be taken as suggestive of
either a skeletal or a smooth muscle origin of this tumor (Foschini et al., 1988; Knuutila
et al., 1998; Miettinen & Ekfors, 1990a; Mukai et al., 1989; Persson et al., 1988).
Loss of 13q21-q22 is especially frequent in low-grade fibromyxoid sarcoma
Losses at 13q, the minimal overlapping area spanning 13q21-22, were seen in six
LGFMS tumors (55%), but not in any other of the sarcoma types. Although loss of 13q21
is the most frequently reported copy number loss in soft tissue sarcomas studied
previously by CGH, (present in approximately 20% of the cases overall), the highest
frequency thus far has been in LMS, which shows this aberration in approximately 53%
of cases (Knuutila et al., 1999; Otano-Joos et al., 2000). Altogether, losses were much
more common in LGFMS than gains, which is untypical of soft tissue sarcomas in
general. Previously, only one LGFMS case with genetic aberrations had been reported, a
tumor showing gains of 7p14-pter, 7q31-q33, and 16p, as well as losses of
chromosomes 18 and 21q and no losses of chromosome 13 (Mezzelani et al., 2000).
The universal phenomenon of 13q losses in various soft tissue sarcomas, including
LGFMS, may indicate a common step in the genetic process of several sarcoma types.
Then again, this aberration appears to be exceptionally frequent in LGFMS, which may
imply an even more LGFMS-specific role for an as-yet-unidentified tumor suppressor
gene or genes located at 13q21. All the losses present in at least two LGFMS cases are
frequent also in MFH, which shares similarities with LGFMS (Larramendy et al., 1997;
Mairal et al., 1999; Parente et al., 1999). Indeed, when discussing the classification of
LGFMS in his report of 12 cases, Evans considered the possibility of LGFMS
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representing a subtype of MFH, but concluded that they belong to different entities
(Evans, 1993).
Gains of 11q13 in Kaposi’s sarcoma indicate amplification of oncogenes from
this restricted area
Four of the ten successfully hybridized Kaposi’s sarcoma tumors (40%) showed gain of
11q13, covering only the q13 band; in two tumors this was the only detectable change.
Gain of 11q13 has been reported in several other soft tissue sarcomas, in which it is
not, however, among the most frequent. In LMS and MFH, the 11q gain is similarly often
restricted to the q13 band (Larramendy et al., 1997; Mairal et al., 1999; Menghi-Sartorio
et al., 2001; Otano-Joos et al., 2000). In breast cancer, in which the amplification of
11q13 is also frequent, the amplicon contains several cores of amplification, one being
centered around the CCND1 gene, and other cores carrying such genes as EMS1,
BCL1, and INT2 (Karlseder et al., 1994; Schuuring et al., 1992). The INT2 gene as well
as the FGF4 gene, also located at 11q13, belong to the fibroblast growth factor family,
whose members have been studied as possible pathogenetic factors in Kaposi’s
sarcoma (Goldman et al., 1997; Murakami-Mori et al., 1998). Because of the previously
observed link between Kaposi’s sarcoma and the FGF genes, as well as the link
between the mouse homolog of INT2 and malignancies caused by a tumor virus, these
two genes, located at 11q13, were further studied by fluorescence in situ hybridization
and immunohistochemistry.
Consistency of 17q and 22q gains in dermatofibrosarcoma protuberans
suggests important roles for these changes
The two most frequent copy number changes seen in our studies (I-V) were gain or
high-level amplification of 17q21-qter, seen in 29% of the samples; and gain or high-
level amplification of 22pter-q13, seen in 21%. The high frequency of these changes
was caused almost exclusively by their high prevalence in DFSP. In addition to DFSP, in
which gain or high-level amplification of 17q21-qter was present in 100% of the cases,
only two Ewing tumors and one ASPS showed this change. Gain or high-level
amplification of 22pter-q13 was present in 79% of the DFSP samples, but in only one
Kaposi’s sarcoma and one Ewing tumor. These findings fit previous cytogenetic findings
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in DFSP, which include ring chromosomes shown to carry material from chromosomes
17 and 22. Furthermore, the starting points of the gains or amplifications on
chromosome 17 were often located around the locus for COL1A1, one of the fusion
gene partners. Previously, gains of 17q segments have been reported in 8/12, and gains
of 22q segments in 10/12 DFSP tumors studied by CGH (Naeem et al., 1995; Pedeutour
et al., 1995).
In other soft tissue sarcomas, gain or high-level amplification of 17q appears
most frequently in LMS and alveolar rhabdomyosarcoma, being seen in approximately
20% of these tumors, although other more recurrent changes are typically seen in both
tumors. In MPNSTs of patients with neurofibromatosis type 1, 17q gain has also been
reported to represent a characteristic change. Chromosome 22 gain is more rare, most
often described in LMS (approximately 12%) (El-Rifai et al., 1998b; Forus et al., 1995;
Gordon et al., 2000; Levy et al., 2000; Otano-Joos et al., 2000; Packenham et al., 1997;
Pandita et al., 1999; Parente et al., 1999; Schmidt et al., 2000; Tarkkanen et al., 1999b;
Weber-Hall et al., 1996).
The high prevalence of 17q and 22q amplifications strongly suggests that the
acquisition of material from these genomic segments has an important impact on the
pathogenesis of DFSP, independent from or associated with the translocation. A finding
suggesting an analogous situation has been reported in alveolar rhabdomyosarcoma,
in which the PAX3-FKHR fusion gene, generated by a specific translocation, was
insufficient for tumor formation in knock-out mice. The authors speculated that additional
genetic events are needed for development of sarcomas (Xie et al., 2001). Amplification
of distinct genes from the 17q21-qter area has been described in several malignancies,
including the genes PAT1, PS6K, SIGMA1B, TBX2, and RAD51C in breast cancer,
PS6K in anaplastic meningioma, and GAS in gastric cancer. The definitive role of these
in the carcinogenesis is, however, still unclear (Bärlund et al., 2000; Cai et al., 2001;
Vidgren et al., 1999; Wu et al., 2000).
Similar changes in typical and fibrosarcomatously transformed
dermatofibrosarcoma protuberans indicate mechanisms other than copy
number changes as acting in tumor progression
Differences in copy number changes between the classical DFSPs and the FS-DFSPs
were evaluated to study possible copy number alterations in tumor progression.
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Differences in the most common changes--17q and 22 gains--between the two groups
were negligible; in fact, the 17q gain was present in every sample in each group. In
addition to the independent importance of these gains in DFSP, these findings suggest
also that the 17q and 22 gains are among the primary genetic aberrations with an
essential role in the early tumorigenetic process, but no substantial role in the
progression of DFSP.
The clearest, although not significant, differences between the two groups were
noted in the total number of aberrations and in the gain of 1p34-pter. An increasing
number of copy number changes have been reported to correlate with tumor
progression in several malignancies such as LMS, GIST, cervical cancer, endometrial
cancer, and renal cell cancer (Allen et al., 2000; El-Rifai et al., 2000; El-Rifai et al., 1998b;
Jiang et al., 2000; Junker et al., 2000; Suehiro et al., 2000). The accumulation of copy
number changes during progression fits well with the multi-step model of
carcinogenesis. The 1p34-pter area is recurrently amplified in the alveolar subtype of
rhabdomyosarcoma, in which the amplicon contains a variant fusion gene partner PAX7
at 1p36, which (alternatively with PAX3 at 2q35) is fused to FKHR at 13q14 (Barr et al.,
1996; Gordon et al., 2000; Weber-Hall et al., 1996). Recurrent gain of 1p34-pter with
PAX7 amplification has also been described in lung carcinoma, but the definite role of
the PAX7 gene or other genes from 1p34-pter in tumor progression has not been
established (Racz et al., 2000).
Although the total number of aberrations in both the DFSP and the FS-DFSP group
was relatively high (mean 4.3 and 5.7 per sample, respectively), no significant
differences were noted between the groups. This may imply that the genetic events
during progression from DFSP to FS-DFSP include other more important genetic
mechanisms undetectable by CGH.
Non-specific gains of 8q and 1q21-q22 may have prognostic value in Ewing
tumors
In Studies I to V, gain of 8q and gain or high-level amplification of 1q21-q22 were present
in 21% and 15% of all samples. The 8q and 1q21-q22 gains appeared in five and four
tumor types, respectively, reflecting the high overall frequency but the lower specificity of
these changes in soft tissue sarcomas. Both changes have been reported in almost all
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soft tissue sarcoma types, as well as in other types of cancer studied by CGH. Both
gains were most frequently seen in the Ewing tumors, in which they were also the most
recurring changes. Gain or high-level amplification of 1q21-q22 was present in five
(18%), and gain of 8q in ten (36%) of the Ewing tumors. In two cases, loss of 16p was
present simultaneously with gain of 1q, which cytogenetically is often seen as a
der(1;16).
In the statistical analysis of the associations between copy number changes and
clinical parameters, a trend towards worse DDFS and overall survival was associated
with 1q21-q22. This association was, however, not statistically significant because of the
small number of patients. Previously, gains at 1q21-q25 have been associated with a
metastatic phenotype or short overall survival in renal clear cell carcinoma, high-grade
osteosarcoma, and prostate cancer (Alers et al., 2000; Gronwald et al., 1997; Tarkkanen
et al., 1999a). The 1q21-q22 area carries several genes with potential significance in
sarcoma pathogenesis, many of which, e.g., the FLG, NTRK1, and SPRR3, have been
shown to be amplified in different types of sarcoma (El-Rifai et al., 2000; Forus et al.,
1998; Knuutila et al., 1998; Mezzelani et al., 2000; Otano-Joos et al., 2000; Pandita et al.,
1999).
The most common change in the Ewing tumors, gain of chromosome 8, was also
associated with a non-significant trend towards worse prognosis. When compared to
the prognosis for patients without 8q gain, this change was seen as lower 5-year DDFS
(40% vs. 65%) and overall survival (45% vs. 63%). Gains of chromosome 8, or parts of it,
have previously been reported to correlate with shorter survival in osteosarcoma, and
with larger tumor size in LMS as well as in synovial sarcoma (El-Rifai et al., 1998b;
Hattinger et al., 1996; Maurici et al., 1998; Mugneret et al., 1988; Skytting et al., 1999b;
Tarkkanen et al., 1999a).
A trend towards worse DDFS was connected also with gain of chromosome 12,
present in three Ewing tumors. Chromosome 12 represents one of the most frequently
gained segments in sarcomas, the most frequent restricted amplicon spanning 12q13-
q15, which harbors several oncogenes known to be amplified in different sarcomas. The
exact roles of these genes in tumor progression are, however, as yet unknown (Knuutila
et al., 1998).
An association of gain or high-level amplification of 6p21.1-pter with poor outcome
was noted; patients with and without this change had a 5-year DDFS of 63% and 0%
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(P=0.04) and overall survival of 64% and 0% (P=0.004), respectively. One of the three
patients with this aberration had metastatic disease at the time of diagnosis, and two
had large central tumors, all representing clinical parameters that have been associated
with poor prognosis. It is thus difficult with this small patient series to estimate the
significance of 6p21.1-pter for prognosis independent of other prognostic markers,
since the aberration may be the cause of other prognostic variables, or be merely a by-
product in the progression of the disease.
Overall, the fact that relatively few copy number changes were present in the
tumors may reflect the significance of the primary genetic event, the translocation, in the
pathogenesis. Recently, study of an extended patient series of 134 Ewing tumor
patients, including the patients of Study V, could confirm a significant association
between gain of 1q and poor prognosis. In addition, gain of chromosome 12 was found
to predict poor outcome in patients with localized disease, and loss of 16q was
significantly associated with disseminated disease at diagnosis. No associations were
established between 6p gain and prognosis (Hattinger et al., unpublished).
9.3. INT2 AND FGF4 ONCOGENES ARE AMPLIFIED AND EXPRESSED IN HUMAN
HERPESVIRUS 8-POSITIVE KAPOSI’S SARCOMA
The HHV-8-specific sequence of the kaposin gene was present in all six samples
tested. This novel herpesvirus was first found to be associated with malignancy when
identified in a Kaposi’s sarcoma skin lesion of an AIDS patient in 1994; it has since
been strongly implicated as a causative factor in Kaposi’s sarcoma and other
malignancies such as primary effusion lymphoma and multicentric Castleman’s
disease (Chang et al., 1994; Dupin et al., 1999; Mayama et al., 1998; Renwick et al.,
1998; Schulz, 1998). HHV-8 belongs to the same herpesviridae family as EBV, a human
tumor virus associated with Burkitt’s lymphoma, nasopharyngeal carcinoma, Hodgkin’s
disease, and possibly other tumors (Butel, 2000). EBV acts by encoding the oncogene
protein LMP1 (latent infection membrane protein 1), which mimics an activated growth
factor receptor and interacts with factors that mediate its proliferative signals (Mosialos
et al., 1995). The mechanistic role of HHV-8 in cancer development is still unclear, but its
genome harbors several genes with homology to the cellular genes involved in cell-cycle
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regulation, cell proliferation, apoptosis, and immune modulation (Boshoff & Chang,
2001).
The INT2 gene, located at 11q13, is a homolog of the mouse oncogene int2; the
int2 oncogene is activated by a tumor virus, MMTV, which integrates a proviral sequence
into the vicinity of the proto-oncogene (Butel, 2000). The FGF4 gene, in close proximity to
INT2 at 11q13, was first identified in Kaposi’s sarcoma cell transfection experiments
(Delli Bovi & Basilico, 1987). Because of these associations--viral tumorigenesis for the
INT2 gene and identification of the FGF4 gene in Kaposi’s sarcoma cells--we chose to
study the amplification and expression of these genes, and found them to be aberrant in
almost all tumors available for these studies. The mean number of FISH signals of the
probes which were carrying both genes was 2.8 per tumor, and immunoreactivity of
either INT2 or FGF4 was present in 8/9 cases.  Amplification of 11q13 has previously
been described in several malignancies, including breast cancer, oral squamous cell
carcinoma, and melanoma. The amplicon harbors the INT2 and FGF4 as well as other
genes like CCND1/PRAD1 and EMS1, which have been shown to be amplified in a
discontinuous way, the amplification and expression pattern varying between different
tumors (Adelaide et al., 1988; Hui et al., 1997; Lese et al., 1995; Shuster et al., 2000;
Szepetowski et al., 1992). Both INT2 and FGF4 are normally expressed during
embryogenesis. Int2 has been connected to inner ear development in the mouse, and
fgf4 participates in limb development in vertebrates (Johnson & Tabin, 1997; Represa et
al., 1991). Thus, the immunoreactivity of either FGF4 or INT2 seen in the Kaposi’s
sarcoma tumors suggests that expression of these genes, possibly caused by
amplification, may play a role in Kaposi’s sarcoma pathogenesis. Although the
mechanism of tumor induction by promoter insertion--such as MMTV provirus integration
leading to int2 activation and subsequent breast cancer in the mouse--appears
uncommon in virus-induced human cancer, the activation of INT2 in the presence of a
novel human tumor virus warrants consideration of similar integration mechanisms, in
addition to the signaling cascade mechanisms suggested in transformation (Chow et
al., 2001; Renne et al., 2001; Samaniego et al., 1998).
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10. CONCLUSIONS AND FUTURE PROSPECTS
This work was aimed at characterizing genetic alterations in rare soft tissue
sarcomas, and evaluating the role of these aberrations in tumor progression and
disease prognosis in appropriate contexts. CGH proved an efficient screening tool for
analyzing archival samples of tumors from which fresh material was unavailable for the
more conventional analyzing methods. In this work, copy number alterations of the very
rare ASPS, LGFMS, and Kaposi’s sarcoma were described for the first time. In addition,
new information on copy number changes in Ewing tumors and DFSP has been added
to that previously available.
After Study I was published, a specific der(17)t(X;17)(p11;q25) of non-reciprocal
nature was reported in ASPS. In one of the tumors in Study I, this translocation was
presumably reflected by a gain of Xp11-pter. Eight of the 13 tumors revealed no DNA
copy number changes, which may indicate that the translocation in some of the tumors
exists in a balanced form. Additional balanced aberrations may also be significant in
ASPS pathogenesis.
LGFMS exhibited an exceptionally frequent loss of 13q21-q22. Although this
alteration is common in various types of sarcomas, its high prevalence in LGFMS may
be indicative of its more specific role in this tumor type. Further studies of this genomic
region with no currently known oncogenes may reveal genes with importance in LGFMS
as well as many other sarcomas.
In Kaposi’s sarcoma, a recurrent gain was found of a restricted chromosomal
region, and two oncogenes from this region with special theoretical interest were further
investigated by FISH and immunohistochemistry. The studies revealed that the INT2 and
FGF4 oncogenes were indeed both amplified and expressed in the tumors. These
findings are of special interest in the context of Kaposi’s sarcoma, its being a
malignancy caused or influenced by a virus whose exact tumorigenic mechanisms are
still unclear. Further studies will be needed to evaluate the oncogenic roles of the
activated human genes INT2 and FGF4 and their functional mechanisms in viral
tumorigenesis.
The specific translocation of DFSP is often located at ring chromosomes carrying
material from the chromosomes involved in the translocation. The finding that gains or
amplifications of the translocation chromosomes are almost exclusively present in the
5 3
tumors strongly suggests that these regions carry oncogenes with primary importance
for tumorigenesis.  Based on similarities between the typical and fibrosarcomatously
transformed tumors, it can instead be concluded that in the progression process copy
number alterations are not important.
In Ewing tumors, copy number gains of 8q and 1q21-q22 were shown to be
associated with trends towards worse prognosis. The number of patients was not
sufficient, however, for revealing statistically significant associations. In addition to these
recurrently described changes in different sarcomas, gain of 6p was associated with
poor prognosis. Because this change was seen in tumors with clinical markers of poor
prognosis, however, the independent value of this gain was not interpretable.  Since new
prognostic markers are of great importance when evaluating these highly malignant
tumors, further analyses will be needed with larger patient series. When evaluating such
a rare malignancy, statistically significant correlations can be achieved only with
international collaboration. Such a trial with an extended patient series has now been
started, and the preliminary results support the finding of 1q gain predicting poor
prognosis for Ewing tumors.
The less specific copy number changes seen in this study are also prevalent in
other subtypes of soft tissue sarcomas. The DNA copy number gains and losses
detected by CGH are in many cases likely to represent unbalanced chromosomal
translocations. Further clarification of the nature of these possibly extremely complex
rearrangements can be conducted with the recently developed FISH techniques such as
multicolor FISH and spectral karyotyping (Schrock et al., 1996; Speicher et al., 1996).
The chromosomal areas with common aberrations may harbor genes playing important
roles in the common pathogenetic pathways of these as well as of other malignancies.
In the future, use of novel array techniques may offer an explicit view of both the specific
as well as the more common target genes within the amplified or lost regions, and the
expression of these genes may be evaluated in detail. Identifying these molecular
mechanisms will undoubtedly lead to the development of drugs specifically targeting the
genetic defects underlying different sarcomas, as is already the case in at least some of
the GISTs.
5 4
11. ACKNOWLEDGEMENTS
This project was accomplished at the Department of Medical Genetics, Haartman
Institute, University of Helsinki. I wish to acknowledge all those who not only made this
work possible, but also, made these years most exciting and enjoyable.
The former and present heads of the Department, Albert de la Chapelle, Helena
Kääriäinen, Juha Kere, Leena Palotie, Pertti Aula, and Anna-Elina Lehesjoki, receive my
thanks for providing me with excellent working facilities within the Department.
I wish to express my deep gratitude to my supervisors Sakari Knuutila, Inkeri Elomaa,
and Juha Kere. I am thankful to Sakari Knuutila for guiding me through this work with
never-ceasing encouragement and commitment. His true enthusiasm and ever-open
door have been a driving force and an opportunity in many instances throughout this
study. I thank Inkeri Elomaa for showing unfailing support for and sincere interest in my
work. Despite her hectic everyday duties, she has always been there for me. I am
grateful to Juha Kere for introducing me to the fascination of genetics in the beginning of
my research, sharing his vast experience, and supporting me, even at unexpected
turning-points during these years.
Ritva Karhu and Helena Willén, the official pre-examiners of this thesis, are gratefully
acknowledged for their thorough review and valuable comments on this thesis.
I warmly thank Carol Norris for author-editing the language of this thesis.
My sincere thanks to all my collaborators in Finland and abroad, especially Markku
Miettinen for his intensive contribution to this work, Maarit Sarlomo-Rikala for pleasant
and fruitful cooperation, Maija Tarkkanen for her invaluable role in Study V and ever-
positive attitude, Waél El-Rifai and Marcelo Larramendy for their unbeatable expertise
and help in the laboratory, and Maria Söderlund as well as Klaus Hedman for their
essential role in Study IV. I wish to thank Tom Böhling, Carl Blomqvist, Martti Virolainen,
Gemma Armengol, Tauno Ekfors, Paula Lindholm, Odd Monge, and Piero Picci for their
contributions as co-authors.
5 5
I wish to thank Anita Ikonen, Yan Aalto, Pirjo Pennanen, and all the others on the 4th floor
of Haartman Institute, for always having been ready to offer help and assistance in so
many ways.
I warmly thank all my friends and colleagues at the Department, both at the University
and at the Clinical Unit, PLY. My special thanks go to Sirpa Ala-Mello, Tarja Joensuu, and
Pia Höglund, for solid and encouraging friendship over the years. Lots of thanks also to
Minna Maunula and Sinikka Lindh for lightening many tough moments with their
energizing attitude.
Hugest thanks to all my Absolutely Fabulous friends outside the Department, especially
my colleagues and dear friends Pia Nordström and Tuuli Nikkarinen, and my close
friend Päivi Nummi-Aho, for sharing their inspiring spirit in moments of joy and sorrow
over the years.
I am grateful to my parents Eija and Risto Kiuru for all their support, particularly their
indispensable assistance in child-care when the kids were younger. I thank my sister
Katja, my brother Harri, and my sister-in-law Minna for their kind helpfulness and
friendship.
Finally, the deepest of all my gratitude goes to my wonderful family: my husband Mats
and our sons Jasper and Rasmus, whom I thank for patiently empathizing with all the
ups and downs of life during these years. Your love and affection is, and will always be,
the most important thing in my life.
The Finnish Cancer Organizations, the Duodecim Foundation, the Sigrid Jusélius
Foundation, the Helsinki University Central Hospital Research Foundation, and Novartis
Finland Inc. are acknowledged for financial support.
Helsinki, February 2002
5 6
12. REFERENCES
Adelaide, J., Mattei, M.G., Marics, I., Raybaud, F., Planche, J., De Lapeyriere, O. &
Birnbaum, D. Chromosomal localization of the hst oncogene and its co-amplification
with the int.2 oncogene in a human melanoma. Oncogene, 2: 413-6. (1988).
Alers, J.C., Rochat, J., Krijtenburg, P.J., Hop, W.C., Kranse, R., Rosenberg, C., Tanke,
H.J., Schroder, F.H. & van Dekken, H. Identification of genetic markers for prostatic
cancer progression. Lab Invest, 80: 931-42. (2000).
Alitalo, K., Schwab, M., Lin, C.C., Varmus, H.E. & Bishop, J.M. Homogeneously staining
chromosomal regions contain amplified copies of an abundantly expressed cellular
oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma.
Proc Natl Acad Sci USA, 80: 1707-11. (1983).
Allen, D.G., White, D.J., Hutchins, A.M., Scurry, J.P., Tabrizi, S.N., Garland, S.M. & Armes,
J.E. Progressive genetic aberrations detected by comparative genomic hybridization
in squamous cell cervical cancer. Br J Cancer, 83: 1659-63. (2000).
Armengol, G., Tarkkanen, M., Virolainen, M., Forus, A., Valle, J., Böhling, T., Asko-
Seljavaara, S., Blomqvist, C., Elomaa, I., Karaharju, E., Kivioja, A.H., Siimes, M.A.,
Tukiainen, E., Caballin, M.R., Myklebost, O. & Knuutila, S. Recurrent gains of 1q, 8 and
12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer,
75: 1403-9. (1997).
Auerbach, H.E. & Brooks, J.J. Alveolar soft part sarcoma. A clinicopathologic and
immunohistochemical study. Cancer, 60: 66-73. (1987).
Barr, F.G., Nauta, L.E., Davis, R.J., Schafer, B.W., Nycum, L.M. & Biegel, J.A. In vivo
amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar
rhabdomyosarcoma. Hum Mol Genet, 5: 15-21. (1996).
Bauer, H.C., Alvegård, T.A., Berlin, Ö., Erlanson, M., Gustafson, P., Kivioja, A., Klepp, R.,
Lehtinen, T., Lindholm, P., Möller, T.R., Rydholm, A., Saeter, G., Trovik, C.S.,
Wahlström, O. & Wiklund, T. The Scandinavian Sarcoma Group Register. Acta Orthop
Scand, 285: 41-4. (1999).
Bedi, G.C., Westra, W.H., Farzadegan, H., Pitha, P.M. & Sidransky, D. Microsatellite
instability in primary neoplasms from HIV + patients. Nat Med, 1: 65-8. (1995).
Bentz, M., Plesch, A., Stilgenbauer, S., Döhner, H. & Lichter, P. Minimal sizes of deletions
detected by comparative genomic hybridization. Genes Chromosom Cancer, 21: 172-
5. (1998).
Beral, V. Epidemiology of Kaposi's sarcoma. Cancer Surveys, 10: 5-22. (1991).
Beral, V. & Newton, R. Overview of the epidemiology of immunodeficiency-associated
cancers. J Natl Cancer Inst. Monographs: 1-6. (1998).
5 7
Berner, J.M., Forus, A., Elkahloun, A., Meltzer, P.S., Fodstad & Myklebost, O. Separate
amplified regions encompassing CDK4 and MDM2 in human sarcomas. Genes
Chromosom Cancer, 17: 254-9. (1996).
Bertazzi, P.A., Zocchetti, C., Guercilena, S., Consonni, D., Tironi, A., Landi, M.T. &
Pesatori, A.C. Dioxin exposure and cancer risk: a 15-year mortality study after the
"Seveso accident". Epidemiology, 8: 646-52. (1997).
Birch, J.M. Li-Fraumeni syndrome. Eur J Cancer, 30A: 1935-41. (1994).
Boman, F., Gultekin, H. & Dickman, P.S. Latent Epstein-Barr virus infection
demonstrated in low-grade leiomyosarcomas of adults with acquired
immunodeficiency syndrome, but not in adjacent Kaposi's lesion or smooth muscle
tumors in immunocompetent patients. Arch Pathol Lab Med, 121: 834-8. (1997).
Boshoff, C. & Chang, Y. Kaposi's sarcoma-associated herpesvirus: a new DNA tumor
virus. Annu Rev Med, 52: 453-70. (2001).
Bridge, J.A., Neff, J.R. & Sandberg, A.A. Cytogenetic analysis of dermatofibrosarcoma
protuberans. Cancer Genet Cytogenet, 49: 199-202. (1990).
Brodeur, G.M., Green, A.A., Hayes, F.A., Williams, K.J., Williams, D.L. & Tsiatis, A.A.
Cytogenetic features of human neuroblastomas and cell lines. Cancer Res, 41: 4678-
86. (1981).
Burt, R.W., DiSario, J.A. & Cannon-Albright, L. Genetics of colon cancer: impact of
inheritance on colon cancer risk. Annu Rev Med, 46: 371-9. (1995).
Butel, J.S. Viral carcinogenesis: revelation of molecular mechanisms and etiology of
human disease. Carcinogenesis, 21: 405-26. (2000).
Bärlund, M., Monni, O., Kononen, J., Cornelison, R., Torhorst, J., Sauter, G., Kallioniemi,
O.-P. & Kallioniemi, A. Multiple genes at 17q23 undergo amplification and
overexpression in breast cancer. Cancer Res, 60: 5340-4. (2000).
Cai, D.X., James, C.D., Scheithauer, B.W., Couch, F.J. & Perry, A. PS6K amplification
characterizes a small subset of anaplastic meningiomas. Am J Clin Pathol, 115: 213-
8. (2001).
Chang, Y., Cesarman, E., Pessin, M.S., Lee, F., Culpepper, J., Knowles, D.M. & Moore,
P.S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's
sarcoma. Science, 266: 1865-1869. (1994).
Chen, J., Silver, D.P., Walpita, D., Cantor, S.B., Gazdar, A.F., Tomlinson, G., Couch, F.J.,
Weber, B.L., Ashley, T., Livingston, D.M. & Scully, R. Stable interaction between the
products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic
cells. Molecular Cell, 2: 317-28. (1998).
5 8
Chow, D., He, X., Snow, A.L., Rose-John, S. & Garcia, K.C. Structure of an extracellular
gp130 cytokine receptor signaling complex. Science, 291: 2150-5. (2001).
Christopherson, W.M., Foote, F.W. & Stewart, F.W. Alveolar soft part sarcoma: Structurally
characteristic tumors of uncertain histogenesis. Cancer, 5: 100-11. (1952).
Clare, N. & Hansen, K. Cytogenetics in the diagnosis of hematologic malignancies.
Hematol Oncol Clin North Am, 8: 785-807. (1994).
Clark, J., Rocques, P.J., Crew, A.J., Gill, S., Shipley, J., Chan, A.M., Gusterson, B.A. &
Cooper, C.S. Identification of novel genes, SYT and SSX, involved in the
t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet, 7:
502-8. (1994).
Clark, S.K., Neale, K.F., Landgrebe, J.C. & Phillips, R.K. Desmoid tumours complicating
familial adenomatous polyposis. Br J Surg, 86: 1185-9. (1999).
Courseaux A, S.P., Fernandes M, Serizet C, Kawaguchi Y, Grosgeorge J, Perucca-
Lostanlen D, Shows TB, Todd JA, Nowak NJ, Gaudray P. Framework YAC contig
anchored into a 3.2-Mb high-resolution physical map in proximal 11q13. Genomics,
40: 13-23. (1996).
Cowell, J.K. Double minutes and homogeneously staining regions: gene amplification
in mammalian cells. Annu Rev Genet, 16: 21-59. (1982).
Crew, A.J., Clark, J., Fisher, C., Gill, S., Grimer, R., Chand, A., Shipley, J., Gusterson, B.A.
& Cooper, C.S. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with
homology to the Kruppel-associated box in human synovial sarcoma. EMBO J, 14:
2333-40. (1995).
Davidson, T., Westbury, G. & Harmer, C.L. Radiation-induced soft-tissue sarcoma. Br J
Surg, 73: 308-9. (1986).
Davis, R.J., D'Cruz, C.M., Lovell, M.A., Biegel, J.A. & Barr, F.G. Fusion of PAX7 to FKHR by
the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer
Res, 54: 2869-72. (1994).
de Leeuw, B., Balemans, M., Olde Weghuis, D. & Geurts van Kessel, A. Identification of
two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-
positive synovial sarcomas. Hum Mol Genet, 4: 1097-9. (1995).
Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H.,
Joubert, I., de Jong, P., Rouleau, G., Aurias, A. & Thomas, G. Gene fusion with an ETS
DNA-binding domain caused by chromosome translocation in human tumours.
Nature, 359: 162-5. (1992).
Delli Bovi, P. & Basilico, C. Isolation of a rearranged human transforming gene following
transfection of Kaposi sarcoma DNA. Proc Natl Acad Sci U S A, 84: 5660-4. (1987).
5 9
DeSchryver-Kecskemeti, K., Kraus, F.T., Engleman, W. & Lacy, P.E. Alveolar soft-part
sarcoma--A malignant angioreninoma: Histochemical, immunocytochemical, and
electron-microscopic study of four cases. Am J Surg Pathol, 6: 5-18. (1982).
Desmond-Hellmann, S.D. & Katongole-Mbidde, E. Kaposi's sarcoma: recent
developments. AIDS, 5: S135-42. (1991).
Devaney, D.M., Dervan, P., O'Neill, S., Carney, D. & Leader, M. Low-grade fibromyxoid
sarcoma. Histopathology, 17: 463-5. (1990).
Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M.,
Capdeville, R. & Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine
kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic
leukemia with the Philadelphia chromosome. N Engl J Med, 344: 1038-42. (2001a).
Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B.,
Kantarjian, H., Capdeville, R., Ohno-Jones, S. & Sawyers, C.L. Efficacy and safety of a
specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl
J Med, 344: 1031-7. (2001b).
Dupin, N., Fisher, C., Kellam, P., Ariad, S., Tulliez, M., Franck, N., van Marck, E., Salmon,
D., Gorin, I., Escande, J.P., Weiss, R.A., Alitalo, K. & Boshoff, C. Distribution of human
herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's
disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A, 96: 4546-51.
(1999).
El-Rifai, W., Larramendy, M.L., Björkqvist, A.-M., Hemmer, S. & Knuutila, S. Optimization
of comparative genomic hybridization using fluorochrome conjugated to dCTP and
dUTP nucleotides. Lab Invest, 77: 699-700. (1997).
El-Rifai, W., Sarlomo-Rikala, M., Andersson, L.C., Knuutila, S. & Miettinen, M. DNA
sequence copy number changes in gastrointestinal stromal tumors: tumor
progression and prognostic significance. Cancer Res, 60: 3899-903. (2000).
El-Rifai, W., Sarlomo-Rikala, M., Andersson, L.C., Miettinen, M. & Knuutila, S. DNA copy
number changes in gastrointestinal stromal tumors--a distinct genetic entity. Ann Chir
Gynaecol, 87: 287-90. (1998a).
El-Rifai, W., Sarlomo-Rikala, M., Knuutila, S. & Miettinen, M. DNA copy number changes
in development and progression in leiomyosarcomas of soft tissues. Am J Pathol,
153: 985-90. (1998b).
Elomaa, I., Blomqvist, C.P., Saeter, G., Åkerman, M., Stenwig, E., Wiebe, T., Björk, O. &
Alvegård, T.A. Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma
Group experience with the SSG IX protocol. Eur J Cancer, 36: 875-80. (2000).
Enzinger, F.M. & Weiss, S.W. (eds) (1995). Soft tissue tumors, 3rd edn. Mosby, St. Louis.
6 0
Evans, H.L. Low-grade fibromyxoid sarcoma. A report of 12 cases. Am J Surg Pathol, 17:
595-600. (1993).
Fingerhut, M.A., Halperin, W.E., Honchar, P.A., Smith, A.B., Groth, D.H. & Russell, W.O. An
evaluation of reports of dioxin exposure and soft tissue sarcoma pathology among
chemical workers in the United States. Scand J Work Environ Health, 10: 299-303.
(1984).
Fletcher, C.D., Åkerman, M., Dal Cin, P., de Wever, I., Mandahl, N., Mertens, F., Mitelman,
F., Rosai, J., Rydholm, A., Sciot, R., Tallini, G., van den Berghe, H., van de Ven, W.,
Vanni, R. & Willén, H. Correlation between clinicopathological features and karyotype
in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology
(CHAMP) Collaborative Study Group. Am J Pathol, 148: 623-30. (1996).
Fletcher, J.A. Cytogenetics and experimental models of sarcomas. Current Opinion in
Oncology, 6: 367-71. (1994).
Folpe, A.L., Lane, K.L., Paull, G. & Weiss, S.W. Low-grade fibromyxoid sarcoma and
hyalinizing spindle cell tumor with giant rosettes: a clinicopathologic study of 73
cases supporting their identity and assessing the impact of high-grade areas. Am J
Surg Pathol, 24: 1353-60. (2000).
Forozan, F., Karhu, R., Kononen, J., Kallioniemi, A. & Kallioniemi, O.P. Genome
screening by comparative genomic hybridization. Trends Genet, 13: 405-9. (1997).
Forus, A., Berner, J.M., Meza-Zepeda, L.A., Saeter, G., Mischke, D., Fodstad & Myklebost,
O. Molecular characterization of a novel amplicon at 1q21-q22 frequently observed in
human sarcomas. Br J Cancer, 78: 495-503. (1998).
Forus, A., Weghuis, D.O., Smeets, D., Fodstad, Myklebost, O. & van Kessel, A.G.
Comparative genomic hybridization analysis of human sarcomas: I. Occurrence of
genomic imbalances and identification of a novel major amplicon at 1q21-q22 in soft
tissue sarcomas. Genes Chromosom Cancer, 14: 8-14. (1995).
Foschini, M.P., Ceccarelli, C., Eusebi, V., Skalli, O. & Gabbiani, G. Alveolar soft part
sarcoma: immunological evidence of rhabdomyoblastic differentiation.
Histopathology, 13: 101-8. (1988).
Galili, N., Davis, R.J., Fredericks, W.J., Mukhopadhyay, S., Rauscher, F.J., 3rd, Emanuel,
B.S., Rovera, G. & Barr, F.G. Fusion of a fork head domain gene to PAX3 in the solid
tumour alveolar rhabdomyosarcoma. Nat Genet, 5: 230-5. (1993).
Gaudray, P., Szepetowski, P., Escot, C., Birnbaum, D. & Theillet, C. DNA amplification at
11q13 in human cancer: from complexity to perplexity. Mutat Res, 276: 317-28. (1992).
Gisselsson, D., Höglund, M., Mertens, F., Johansson, B., Dal Cin, P., Van den Berghe,
H., Earnshaw, W.C., Mitelman, F. & Mandahl, N. The structure and dynamics of ring
chromosomes in human neoplastic and non-neoplastic cells. Hum Genet, 104: 315-
25. (1999).
6 1
Goldman, C.K., Rogers, B.E., Douglas, J.T., Sosnowski, B.A., Ying, W., Siegal, G.P.,
Baird, A., Campain, J.A. & Curiel, D.T. Targeted gene delivery to Kaposi's sarcoma
cells via the fibroblast growth factor receptor. Cancer Res, 57: 1447-51. (1997).
Goodlad, J.R., Mentzel, T. & Fletcher, C.D. Low grade fibromyxoid sarcoma:
clinicopathological analysis of eleven new cases in support of a distinct entity.
Histopathology, 26: 229-37. (1995).
Gordon, A.T., Brinkschmidt, C., Anderson, J., Coleman, N., Dockhorn-Dworniczak, B.,
Pritchard-Jones, K. & Shipley, J. A novel and consistent amplicon at 13q31
associated with alveolar rhabdomyosarcoma. Genes Chromosom Cancer, 28: 220-6.
(2000).
Gronwald, J., Storkel, S., Holtgreve-Grez, H., Hadaczek, P., Brinkschmidt, C., Jauch, A.,
Lubinski, J. & Cremer, T. Comparison of DNA gains and losses in primary renal clear
cell carcinomas and metastatic sites: importance of 1q and 3p copy number changes
in metastatic events. Cancer Res, 57: 481-7. (1997).
Harms, D. Soft tissue sarcomas in the Kiel Pediatric Tumor Registry. Curr Top Pathol,
89: 31-45. (1995).
Harwood, A.R., Osoba, D., Hofstader, S.L., Goldstein, M.B., Cardella, C.J., Holecek, M.J.,
Kunynetz, R. & Giammarco, R.A. Kaposi's sarcoma in recipients of renal transplants.
Am J Med, 67: 759-65. (1979).
Hashimoto, H. Incidence of soft tissue sarcomas in adults. Curr Top Pathol, 89: 1-16.
(1995).
Hattinger, C.M., Pötscher, U., Squire, J., Tarkkanen, M., Zielenska, M., Kiuru-Kuhlefelt, S.,
Kager, L., Knuutila, S., Niggli, F., Ambros, P.F., Gadner, H., Betts, D. & Thorner, P.
Prognostic impact of chromosomal aberrations in Ewing tumors. Submitted.
Hattinger, C.M., Rumpler, S., Strehl, S., Ambros, I.M., Zoubek, A., Stark, B., Koscielniak,
E., Gadner, H. & Ambros, P.F. Chromosomal aberrations in Ewing tumors: an
evaluation by conventional cytogenetics and in situ hybridization techniques. 5th
European Workshop on Cytogenetics and Molecular Genetics of Human Solid
Tumours, Baveno, Italy: 173. (1996).
Heim, S., Mandahl, N., Rydholm, A., Willén, H. & Mitelman, F. Different karyotypic features
characterize different clinico-pathologic subgroups of benign lipogenic tumors. Int J
Cancer, 42: 863-7. (1988).
Heim, S. & Mitelman, F. Cancer Cytogenetics, 2nd edn. Wiley-Liss, New York.
Hemminki, A., Markie, D., Tomlinson, I., Avizienyte, E., Roth, S., Loukola, A., Bignell, G.,
Warren, W., Aminoff, M., Höglund, P., Järvinen, H., Kristo, P., Pelin, K., Ridanpää, M.,
Salovaara, R., Toro, T., Bodmer, W., Olschwang, S., Olsen, A.S., Stratton, M.R., de la
6 2
Chapelle, A. & Aaltonen, L.A. A serine/threonine kinase gene defective in Peutz-
Jeghers syndrome. Nature, 391: 184-7. (1998).
Hill, M.A., Araya, J.C., Eckert, M.W., Gillespie, A.T., Hunt, J.D. & Levine, E.A. Tumor specific
Epstein-Barr virus infection is not associated with leiomyosarcoma in human
immunodeficiency virus negative individuals. Cancer, 80: 204-10. (1997).
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K.,
Hanada, M., Kurata, A., Takeda, M., Muhammad Tunio, G., Matsuzawa, Y., Kanakura,
Y., Shinomura, Y. & Kitamura, Y. Gain-of-function mutations of c-kit in human
gastrointestinal stromal tumors. Science, 279: 577-80. (1998).
Hope, D.G. & Mulvihill, J.J. Malignancy in neurofibromatosis. Adv Neurol, 29: 33-56.
(1981).
Hui, R., Campbell, D.H., Lee, C.S., McCaul, K., Horsfall, D.J., Musgrove, E.A., Daly, R.J.,
Seshadri, R. & Sutherland, R.L. EMS1 amplification can occur independently of
CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in
primary breast cancer. Oncogene, 15: 1617-23. (1997).
Huson, S.M., Compston, D.A. & Harper, P.S. A genetic study of von Recklinghausen
neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. J Med
Genet, 26: 712-21. (1989).
Inagaki, H., Nagasaka, T., Otsuka, T., Sugiura, E., Nakashima, N. & Eimoto, T.
Association of SYT-SSX fusion types with proliferative activity and prognosis in
synovial sarcoma. Mod Pathol, 13: 482-8. (2000).
Isola, J.J., Kallioniemi, O.P., Chu, L.W., Fuqua, S.A., Hilsenbeck, S.G., Osborne, C.K. &
Waldman, F.M. Genetic aberrations detected by comparative genomic hybridization
predict outcome in node-negative breast cancer. Am J Pathol, 147: 905-11. (1995).
Jeon, I.S., Davis, J.N., Braun, B.S., Sublett, J.E., Roussel, M.F., Denny, C.T. & Shapiro,
D.N. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS
gene ETV1. Oncogene, 10: 1229-34. (1995).
Jiang, F., Desper, R., Papadimitriou, C.H., Schaffer, A.A., Kallioniemi, O.P., Richter, J.,
Schraml, P., Sauter, G., Mihatsch, M.J. & Moch, H. Construction of evolutionary tree
models for renal cell carcinoma from comparative genomic hybridization data. Cancer
Res, 60: 6503-9. (2000).
Joensuu, H., Roberts, P.J., Sarlomo-Rikala, M., Andersson, L.C., Tervahartiala, P.,
Tuveson, D., Silberman, S., Capdeville, R., Dimitrijevic, S., Druker, B. & Demetri, G.D.
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic
gastrointestinal stromal tumor. N Engl J Med, 344: 1052-6. (2001).
Johnson, R.L. & Tabin, C.J. Molecular models for vertebrate limb development. Cell, 90:
979-90. (1997).
6 3
Joyama, S., Ueda, T., Shimizu, K., Kudawara, I., Mano, M., Funai, H., Takemura, K. &
Yoshikawa, H. Chromosome rearrangement at 17q25 and xp11.2 in alveolar soft-part
sarcoma: A case report and review of the literature. Cancer, 86: 1246-50. (1999).
Junker, K., Moravek, P., Podhola, M., Weirich, G., Hindermann, W., Janitzky, V. & Schubert,
J. Genetic alterations in metastatic renal cell carcinoma detected by comparative
genomic hybridization: correlation with clinical and histological data. Int J Oncol, 17:
903-8. (2000).
Kainu, T., Juo, S.H., Desper, R., Schaffer, A.A., Gillanders, E., Rozenblum, E., Freas-Lutz,
D., Weaver, D., Stephan, D., Bailey-Wilson, J., Kallioniemi, O.P., Tirkkonen, M.,
Syrjäkoski, K., Kuukasjarvi, T., Koivisto, P., Karhu, R., Holli, K., Arason, A.,
Johannesdottir, G., Bergthorsson, J.T., Johannsdottir, H., Egilsson, V., Barkardottir,
R.B., Johannsson, O., Haraldsson, K., Sandberg, T., Holmberg, E., Grönberg, H.,
Olsson, H., Borg, A., Vehmanen, P., Eerola, H., Heikkila, P., Pyrhönen, S. &
Nevanlinna, H. Somatic deletions in hereditary breast cancers implicate 13q21 as a
putative novel breast cancer susceptibility locus. Proc Natl Acad Sci U S A, 97: 9603-
9608. (2000).
Kallioniemi, A., Kallioniemi, O.P., Sudar, D., Rutovitz, D., Gray, J.W., Waldman, F. &
Pinkel, D. Comparative genomic hybridization for molecular cytogenetic analysis of
solid tumors. Science, 258: 818-21. (1992).
Kallioniemi, O.P., Kallioniemi, A., Piper, J., Isola, J., Waldman, F.M., Gray, J.W. & Pinkel,
D. Optimizing comparative genomic hybridization for analysis of DNA sequence copy
number changes in solid tumors. Genes Chromosom Cancer, 10: 231-43. (1994).
Kaneko, Y., Yoshida, K., Handa, M., Toyoda, Y., Nishihira, H., Tanaka, Y., Sasaki, Y.,
Ishida, S., Higashino, F. & Fujinaga, K. Fusion of an ETS-family gene, EIAF, to EWS by
t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of
infancy. Genes Chromosom Cancer, 15: 115-21. (1996).
Karlseder, J., Zeillinger, R., Schneeberger, C., Czerwenka, K., Speiser, P., Kubista, E.,
Birnbaum, D., Gaudray, P. & Theillet, C. Patterns of DNA amplification at band q13 of
chromosome 11 in human breast cancer. Genes Chromosom Cancer, 9: 42-8.
(1994).
Kerr, B., Eden, O.B., Dandamudi, R., Shannon, N., Quarrell, O., Emmerson, A.,
Ladusans, E., Gerrard, M. & Donnai, D. Costello syndrome: two cases with embryonal
rhabdomyosarcoma. J Med Genet, 35: 1036-9. (1998).
King, A.A., Debaun, M.R., Riccardi, V.M. & Gutmann, D.H. Malignant peripheral nerve
sheath tumors in neurofibromatosis 1. Am J Med Genet, 93: 388-92. (2000).
Kinzler, K.W. & Vogelstein, B. Cancer-susceptibility genes. Gatekeepers and caretakers.
Nature, 386: 761- 763. (1997).
Knezevich, S.R., McFadden, D.E., Tao, W., Lim, J.F. & Sorensen, P.H. A novel ETV6-
NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet, 18: 184-7. (1998).
6 4
Knight, J.C., Renwick, P.J., Cin, P.D., Van den Berghe, H. & Fletcher, C.D. Translocation
t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and
cytogenetic analysis. Cancer Res, 55: 24-7. (1995).
Knudson, A.G., Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl
Acad Sci USA, 68: 820-3. (1971).
Knuutila, S., Aalto, Y., Autio, K., Björkqvist, A.M., El-Rifai, W., Hemmer, S., Huhta, T.,
Kettunen, E., Kiuru-Kuhlefelt, S., Larramendy, M.L., Lushnikova, T., Monni, O., Pere, H.,
Tapper, J., Tarkkanen, M., Varis, A., Wasenius, V.M., Wolf, M. & Zhu, Y. DNA copy
number losses in human neoplasms. Am J Pathol, 155: 683-94. (1999).
Knuutila, S., Björkqvist, A.-M., Autio, K., Tarkkanen, M., Wolf, M., Monni, O., Szymanska, J.,
Larramendy, M.L., Tapper, J., Pere, H., El-Rifai, W., Hemmer, S., Wasenius, V.M.,
Vidgren, V. & Zhu, Y. DNA copy number amplifications in human neoplasms. Review
of comparative genomic hybridization studies. Am J Pathol, 152: 1107-1123. (1998).
Kransdorf, M.J. Malignant soft-tissue tumors in a large referral population: distribution of
diagnoses by age, sex, and location. AJR Am J Roentgenol, 164: 129-34. (1995).
Labelle, Y., Zucman, J., Stenman, G., Kindblom, L.G., Knight, J., Turc-Carel, C.,
Dockhorn-Dworniczak, B., Mandahl, N., Desmaze, C. & Peter, M. Oncogenic
conversion of a novel orphan nuclear receptor by chromosome translocation. Hum
Mol Genet, 4: 2219-26. (1995).
Ladanyi, M. & Gerald, W. Fusion of the EWS and WT1 genes in the desmoplastic small
round cell tumor. Cancer Res, 54: 2837-40. (1994).
Ladanyi, M., Lui, M.Y., Antonescu, C.R., Krause-Boehm, A., Meindl, A., Argani, P., Healey,
J.H., Ueda, T., Yoshikawa, H., Meloni-Ehrig, A., Sorensen, P.H., Mertens, F., Mandahl,
N., van den Berghe, H., Sciot, R., Cin, P.D. & Bridge, J. The der(17)t(X;17)(p11;q25) of
human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a
novel gene at 17q25. Oncogene, 20: 48-57. (2001).
Lane, K.L., Shannon, R.J. & Weiss, S.W. Hyalinizing spindle cell tumor with giant
rosettes: a distinctive tumor closely resembling low-grade fibromyxoid sarcoma. Am J
Surg Pathol, 21: 1481-8. (1997).
Larramendy, M.L., Tarkkanen, M., Blomqvist, C., Virolainen, M., Wiklund, T., Asko-
Seljavaara, S., Elomaa, I. & Knuutila, S. Comparative genomic hybridization of
malignant fibrous histiocytoma reveals a novel prognostic marker. Am J Pathol, 151:
1153-61. (1997).
Laskin, W.B., Silverman, T.A. & Enzinger, F.M. Postradiation soft tissue sarcomas. An
analysis of 53 cases. Cancer, 62: 2330-40. (1988).
6 5
Lawrence, W., Jr., Donegan, W.L., Natarajan, N., Mettlin, C., Beart, R. & Winchester, D.
Adult soft tissue sarcomas. A pattern of care survey of the American College of
Surgeons. Ann Surg, 205: 349-59. (1987).
Lese, C.M., Rossie, K.M., Appel, B.N., Reddy, J.K., Johnson, J.T., Myers, E.N. & Gollin,
S.M. Visualization of INT2 and HST1 amplification in oral squamous cell carcinomas.
Genes Chromosom Cancer, 12: 288-95. (1995).
Levine, E.A. Prognostic factors in soft tissue sarcoma. Semin Surg Oncol, 17: 23-32.
(1999).
Levy, B., Mukherjee, T. & Hirschhorn, K. Molecular cytogenetic analysis of uterine
leiomyoma and leiomyosarcoma by comparative genomic hybridization. Cancer
Genet Cytogenet, 121: 1-8. (2000).
Li, F.P. & Fraumeni, J.F., Jr. Prospective study of a family cancer syndrome. Jama, 247:
2692-4. (1982).
Lieberman, P.H., Brennan, M.F., Kimmel, M., Erlandson, R.A., Garin-Chesa, P. &
Flehinger, B.Y. Alveolar soft-part sarcoma. A clinico-pathologic study of half a century.
Cancer, 63: 1-13. (1989).
Lux, M.L., Rubin, B.P., Biase, T.L., Chen, C.J., Maclure, T., Demetri, G., Xiao, S., Singer,
S., Fletcher, C.D. & Fletcher, J.A. KIT extracellular and kinase domain mutations in
gastrointestinal stromal tumors. Am J Pathol, 156: 791-5. (2000).
Mairal, A., Terrier, P., Chibon, F., Sastre, X., Lecesne, A. & Aurias, A. Loss of
chromosome 13 is the most frequent genomic imbalance in malignant fibrous
histiocytomas. A comparative genomic hybridization analysis of a series of 30 cases.
Cancer Genet Cytogenet, 111: 134-8. (1999).
Mandahl, N., Heim, S., Willén, H., Rydholm, A. & Mitelman, F. Supernumerary ring
chromosome as the sole cytogenetic abnormality in a dermatofibrosarcoma
protuberans. Cancer Genet Cytogenet, 49: 273-5. (1990).
Martin, J.N., Ganem, D.E., Osmond, D.H., Page-Shafer, K.A., Macrae, D. & Kedes, D.H.
Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl
J Med, 338: 948-54. (1998).
Maurici, D., Perez-Atayde, A., Grier, H.E., Baldini, N., Serra, M. & Fletcher, J.A. Frequency
and implications of chromosome 8 and 12 gains in Ewing sarcoma. Cancer Genet
Cytogenet, 100: 106-10. (1998).
Mayama, S., Cuevas, L.E., Sheldon, J., Omar, O.H., Smith, D.H., Okong, P., Silvel, B.,
Hart, C.A. & Schulz, T.F. Prevalence and transmission of Kaposi's sarcoma-
associated herpesvirus (human herpesvirus 8) in Ugandan children and
adolescents. Int J Cancer, 77: 817-20. (1998).
6 6
Menghi-Sartorio, S., Mandahl, N., Mertens, F., Picci, P. & Knuutila, S. DNA copy number
amplifications in sarcomas with homogeneously staining regions and double
minutes. Cytometry, 46: 79-84. (2001).
Mentzel, T., Beham, A., Katenkamp, D., Dei Tos, A.P. & Fletcher, C.D. Fibrosarcomatous
("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and
immunohistochemical study of a series of 41 cases with emphasis on prognostic
significance. Am J Surg Pathol, 22: 576-587. (1998).
Mezzelani, A., Sozzi, G., Nessling, M., Riva, C., Della Torre, G., Testi, M.A., Azzarelli, A.,
Pierotti, M.A., Lichter, P. & Pilotti, S. Low grade fibromyxoid sarcoma. a further low-
grade soft tissue malignancy characterized by a ring chromosome. Cancer Genet
Cytogenet, 122: 144-8. (2000).
Miettinen, M. & Ekfors, T. Alveolar soft part sarcoma. Immunohistochemical evidence for
muscle cell differentiation. Am J Clin Pathol, 93: 32-8. (1990a).
Miettinen, M. & Ekfors, T. Alveolar soft part sarcoma. Immunohistochemical evidence for
muscle cell differentiation [see comments]. Am J Clin Pathol, 93: 32-8. (1990b).
Miller, S.A., Dykes, D.D. & Polesky, H.F. A simple salting out procedure for
extracting DNA from human nucleated cells.  Nucleic Acids Res, 16: 1215. (1988).
Milner, J., Ponder, B., Hughes-Davies, L., Seltmann, M. & Kouzarides, T. Transcriptional
activation functions in BRCA2. Nature, 386: 772-3. (1997).
Minoletti, F., Miozzo, M., Pedeutour, F., Sard, L., Pilotti, S., Azzarelli, A., Turc-Carel, C.,
Pierotti, M.A. & Sozzi, G. Involvement of chromosomes 17 and 22 in
dermatofibrosarcoma protuberans. Genes Chromosom Cancer, 13: 62-5. (1995).
Mitelman, F. Catalog of chromosome aberrations in cancer, 6th edn. Wiley-Liss, New
York.
Moch, H., Presti, J.C., Jr., Sauter, G., Buchholz, N., Jordan, P., Mihatsch, M.J. & Waldman,
F.M. Genetic aberrations detected by comparative genomic hybridization are
associated with clinical outcome in renal cell carcinoma. Cancer Res, 56: 27-30.
(1996).
Mosialos, G., Birkenbach, M., Yalamanchili, R., VanArsdale, T., Ware, C. & Kieff, E. The
Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the
tumor necrosis factor receptor family. Cell, 80: 389-99. (1995).
Mugneret, F., Lizard, S., Aurias, A. & Turc-Carel, C. Chromosomes in Ewing's sarcoma.
II. Nonrandom additional changes, trisomy 8 and der(16)t(1;16). Cancer Genet
Cytogenet, 32: 239-45. (1988).
Mukai, M., Torikata, C., Iri, H., Mikata, A., Hanaoka, H., Kato, K. & Kageyama, K.
Histogenesis of alveolar soft part sarcoma. An immunohistochemical and
biochemical study. Am J Surg Pathol, 10: 212-8. (1986).
6 7
Mukai, M., Torikata, C., Shimoda, T. & Iri, H. Alveolar soft part sarcoma. Assessment of
immunohistochemical demonstration of desmin using paraffin sections and frozen
sections. Virchows Arch A Pathol Anat Histopathol, 414: 503-9. (1989).
Mulligan, L.M., Matlashewski, G.J., Scrable, H.J. & Cavenee, W.K. Mechanisms of p53
loss in human sarcomas. Proc Natl Acad Sci USA, 87: 5863-7. (1990).
Murakami-Mori, K., Mori, S. & Nakamura, S. Endogenous basic fibroblast growth factor is
essential for cyclin E- CDK2 activity in multiple external cytokine-induced proliferation
of AIDS-associated Kaposi's sarcoma cells: dual control of AIDS-associated Kaposi's
sarcoma cell growth and cyclin E-CDK2 activity by endogenous and external signals.
J Immunol, 161: 1694-704. (1998).
Naeem, R., Lux, M.L., Huang, S.F., Naber, S.P., Corson, J.M. & Fletcher, J.A. Ring
chromosomes in dermatofibrosarcoma protuberans are composed of interspersed
sequences from chromosomes 17 and 22. Am J Pathol, 147: 1553-8. (1995).
Nakano, H., Tateishi, A., Imamura, T., Miki, H., Ohno, T., Moue, T., Sekiguchi, M., Unno, K.,
Abe, S., Matsushita, T., Katoh, Y. & Itoh, T. RT-PCR suggests human skeletal muscle
origin of alveolar soft-part sarcoma. Oncology, 58: 319-23. (2000).
Nilbert, M. Molecular and cytogenetics of soft tissue sarcomas. Acta Orthop Scand, 273:
60-7. (1997).
Nilsson, G., Skytting, B., Xie, Y., Brodin, B., Perfekt, R., Mandahl, N., Lundeberg, J., Uhlén,
M. & Larsson, O. The SYT-SSX1 variant of synovial sarcoma is associated with a high
rate of tumor cell proliferation and poor clinical outcome. Cancer Res, 59: 3180-4.
(1999).
O'Sullivan, M.J., Kyriakos, M., Zhu, X., Wick, M.R., Swanson, P.E., Dehner, L.P.,
Humphrey, P.A. & Pfeifer, J.D. Malignant peripheral nerve sheath tumors with t(X;18). A
pathologic and molecular genetic study. Mod Pathol, 13: 1336-46. (2000).
Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L. & Vogelstein, B. Amplification of a
gene encoding a p53-associated protein in human sarcomas. Nature, 358: 80-3.
(1992).
Otano-Joos, M., Mechtersheimer, G., Ohl, S., Wilgenbus, K.K., Scheurlen, W., Lehnert, T.,
Willeke, F., Otto, H.F., Lichter, P. & Joos, S. Detection of chromosomal imbalances in
leiomyosarcoma by comparative genomic hybridization and interphase cytogenetics.
Cytogenet Cell Genet, 90: 86-92. (2000).
Packenham, J.P., du Manoir, S., Schröck, E., Risinger, J.I., Dixon, D., Denz, D.N., Evans,
J.A., Berchuck, A., Barrett, J.C., Devereux, T.R. & Ried, T. Analysis of genetic
alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic
hybridization. Mol Carcinog, 19: 273-9. (1997).
6 8
Panagopoulos, I., Höglund, M., Mertens, F., Mandahl, N., Mitelman, F. & Åman, P. Fusion
of the EWS and CHOP genes in myxoid liposarcoma. Oncogene, 12: 489-94. (1996).
Panagopoulos, I., Mencinger, M., Dietrich, C.U., Bjerkehagen, B., Saeter, G., Mertens, F.,
Mandahl, N. & Heim, S. Fusion of the RBP56 and CHN genes in extraskeletal myxoid
chondrosarcomas with translocation t(9;17)(q22;q11). Oncogene, 18: 7594-8. (1999).
Pandita, A., Zielenska, M., Thorner, P., Bayani, J., Godbout, R., Greenberg, M. & Squire,
J.A. Application of comparative genomic hybridization, spectral karyotyping, and
microarray analysis in the identification of subtype-specific patterns of genomic
changes in rhabdomyosarcoma. Neoplasia, 1: 262-75. (1999).
Parente, F., Grosgeorge, J., Coindre, J.M., Terrier, P., Vilain, O. & Turc-Carel, C.
Comparative genomic hybridization reveals novel chromosome deletions in 90
primary soft tissue tumors. Cancer Genet Cytogenet, 115: 89-95. (1999).
Pedeutour, F., Coindre, J.M., Sozzi, G., Nicolo, G., Leroux, A., Toma, S., Miozzo, M.,
Bouchot, C., Hecht, F., Ayraud, N. & Turc-Carel, C. Supernumerary ring chromosomes
containing chromosome 17 sequences. A specific feature of dermatofibrosarcoma
protuberans? Cancer Genet Cytogenet, 76: 1-9. (1994).
Pedeutour, F., Simon, M.P., Minoletti, F., Sozzi, G., Pierotti, M.A., Hecht, F. & Turc-Carel, C.
Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers
of chromosome 17 and 22 sequences. Cancer Res, 55: 2400-3. (1995).
Persson, S., Willems, J.S., Kindblom, L.G. & Angervall, L. Alveolar soft part sarcoma. An
immunohistochemical, cytologic and electron-microscopic study and a quantitative
DNA analysis. Virchows Arch A Pathol Anat Histopathol, 412: 499-513. (1988).
Peter, M., Couturier, J., Pacquement, H., Michon, J., Thomas, G., Magdelenat, H. &
Delattre, O. A new member of the ETS family fused to EWS in Ewing tumors.
Oncogene, 14: 1159-64. (1997).
Pisters, P.W. & Pollock, R.E. Staging and prognostic factors in soft tissue sarcoma.
Seminars in Radiation Oncology, 9: 307-14. (1999).
Qunibi, W.Y., Barri, Y., Alfurayh, O., Almeshari, K., Khan, B., Taher, S. & Sheth, K. Kaposi's
sarcoma in renal transplant recipients: a report on 26 cases from a single institution.
Transplant Proc, 25: 1402-5. (1993).
Rabbitts, T.H., Forster, A., Larson, R. & Nathan, P. Fusion of the dominant negative
transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in
malignant liposarcoma. Nat Genet, 4: 175-80. (1993).
Racz, A., Brass, N., Hofer, M., Sybrecht, G.W., Remberger, K. & Meese, E.U. Gene
amplification at chromosome 1pter-p33 including the genes PAX7 and ENO1 in
squamous cell lung carcinoma. Int J Oncol, 17: 67-73. (2000).
6 9
Reissmann, P.T., Simon, M.A., Lee, W.H. & Slamon, D.J. Studies of the retinoblastoma
gene in human sarcomas. Oncogene, 4: 839-43. (1989).
Renne, R., Barry, C., Dittmer, D., Compitello, N., Brown, P.O. & Ganem, D. Modulation of
cellular and viral gene expression by the latency- associated nuclear antigen of
Kaposi's sarcoma-associated herpesvirus. J Virol, 75: 458-68. (2001).
Renwick, N., Halaby, T., Weverling, G.J., Dukers, N.H., Simpson, G.R., Coutinho, R.A.,
Lange, J.M., Schulz, T.F. & Goudsmit, J. Seroconversion for human herpesvirus 8
during HIV infection is highly predictive of Kaposi's sarcoma. AIDS, 12: 2481-8.
(1998).
Represa, J., Leon, Y., Miner, C. & Giraldez, F. The int-2 proto-oncogene is responsible for
induction of the inner ear. Nature, 353: 561-3. (1991).
Risinger, J.I., Umar, A., Boyer, J.C., Evans, A.C., Berchuck, A., Kunkel, T.A. & Barrett, J.C.
Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine
sarcoma cell lines defective in mismatch repair activity. Cancer Res, 55: 5664-9.
(1995).
Robinson, E., Neugut, A.I. & Wylie, P. Clinical aspects of postirradiation sarcomas. J Natl
Cancer Inst, 80: 233-40. (1988).
Rogatsch, H., Bonatti, H., Menet, A., Larcher, C., Feichtinger, H. & Dirnhofer, S. Epstein-
Barr virus-associated multicentric leiomyosarcoma in an adult patient after heart
transplantation: case report and review of the literature. Am J Surg Pathol, 24: 614-21.
(2000).
Rosai, J., Åkerman, M., Dal Cin, P., DeWever, I., Fletcher, C.D., Mandahl, N., Mertens, F.,
Mitelman, F., Rydholm, A., Sciot, R., Tallini, G., Van den Berghe, H., Van de Ven, W.,
Vanni, R. & Willén, H. Combined morphologic and karyotypic study of 59 atypical
lipomatous tumors. Evaluation of their relationship and differential diagnosis with
other adipose tissue tumors (a report of the CHAMP Study Group). Am J Surg Pathol,
20: 1182-9. (1996).
Russell, W.O., Cohen, J., Enzinger, F., Hajdu, S.I., Heise, H., Martin, R.G., Meissner, W.,
Miller, W.T., Schmitz, R.L. & Suit, H.D. A clinical and pathological staging system for
soft tissue sarcomas. Cancer, 40: 1562-70. (1977).
Rydholm, A., Gustafson, P., Alvegård, T.A., Saeter, G. & Blomqvist, C. Prognostic factors
in soft tissue sarcoma. A review and the Scandinavian Sarcoma Group experience.
Acta Orthop Scand, 285: 50-7. (1999).
Safai, B. & Good, R.A. Kaposi's sarcoma: a review and recent developments. CA-Cancer
J Clin, 31: 2-12. (1981).
Samaniego, F., Markham, P.D., Gendelman, R., Watanabe, Y., Kao, V., Kowalski, K.,
Sonnabend, J.A., Pintus, A., Gallo, R.C. & Ensoli, B. Vascular endothelial growth factor
and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by
7 0
inflammatory cytokines and synergize to promote vascular permeability and KS lesion
development. Am J Pathol, 152: 1433-43. (1998).
Sandberg, A.A. The chromosomes in human cancer and leukemia, 2nd edn. Elsevier,
New York.
Saracci, R., Kogevinas, M., Bertazzi, P.-A., Bueno de Mesquita, B.H., Coggon, D., Green,
L.M., Kauppinen, T., L'Abbé, K.A., Littorin, M. & Lynge, E. Cancer mortality in workers
exposed to chlorophenoxy herbicides and chlorophenols. Lancet, 338: 1027-32.
(1991).
Sarlomo-Rikala, M., El-Rifai, W., Lahtinen, T., Andersson, L.C., Miettinen, M. & Knuutila,
S. Different patterns of DNA copy number changes in gastrointestinal stromal tumors,
leiomyomas, and schwannomas. Hum Pathol, 29: 476-81. (1998).
Schmidt, D., Herrmann, C., Jurgens, H. & Harms, D. Malignant peripheral
neuroectodermal tumor and its necessary distinction from Ewing's sarcoma. A report
from the Kiel Pediatric Tumor Registry. Cancer, 68: 2251-9. (1991).
Schmidt, H., Taubert, H., Meye, A., Wurl, P., Bache, M., Bartel, F., Holzhausen, H.J. &
Hinze, R. Gains in chromosomes 7, 8q, 15q and 17q are characteristic changes in
malignant but not in benign peripheral nerve sheath tumors from patients with
Recklinghausen's disease. Cancer Lett, 155: 181-90. (2000).
Schrock, E., du Manoir, S., Veldman, T., Schoell, B., Wienberg, J., Ferguson-Smith, M.A.,
Ning, Y., Ledbetter, D.H., Bar-Am, I., Soenksen, D., Garini, Y. & Ried, T. Multicolor
spectral karyotyping of human chromosomes. Science, 273: 494-7. (1996).
Schulz, T.F. Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). J Gen
Virol, 79: 1573-91. (1998).
Schulz, T.F. & Moore, P.S. Kaposi's sarcoma-associated herpesvirus: a new human
tumor virus, but how? Trends Microbiol, 7: 196-200. (1999).
Schuuring, E., Verhoeven, E., Mooi, W.J. & Michalides, R.J. Identification and cloning of
two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified
chromosome 11q13 region in human carcinomas. Oncogene, 7: 355-61. (1992).
Sharan, S.K., Morimatsu, M., Albrecht, U., Lim, D.S., Regel, E., Dinh, C., Sands, A.,
Eichele, G., Hasty, P. & Bradley, A. Embryonic lethality and radiation hypersensitivity
mediated by Rad51 in mice lacking Brca2. Nature, 386: 804-10. (1997).
Shuster, M.I., Han, L., Le Beau, M.M., Davis, E., Sawicki, M., Lese, C.M., Park, N.H.,
Colicelli, J. & Gollin, S.M. A consistent pattern of RIN1 rearrangements in oral
squamous cell carcinoma cell lines supports a breakage-fusion-bridge cycle model
for 11q13 amplification. Genes Chromosom Cancer, 28: 153-63. (2000).
Simon, M.P., Pedeutour, F., Sirvent, N., Grosgeorge, J., Minoletti, F., Coindre, J.M., Terrier-
Lacombe, M.J., Mandahl, N., Craver, R.D., Blin, N., Sozzi, G., Turc-Carel, C., O'Brien,
7 1
K.P., Kedra, D., Fransson, I., Guilbaud, C. & Dumanski, J.P. Deregulation of the
platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in
dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet, 15: 95-8.
(1997).
Skytting, B. Synovial sarcoma. A Scandinavian Sarcoma Group project. Acta Orthop
Scand, 291: 1-28. (2000).
Skytting, B., Nilsson, G., Brodin, B., Xie, Y., Lundeberg, J., Uhlén, M. & Larsson, O. A novel
fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst, 91: 974-5. (1999a).
Skytting, B.T., Szymanska, J., Aalto, Y., Lushnikova, T., Blomqvist, C., Elomaa, I., Larsson,
O. & Knuutila, S. Clinical importance of genomic imbalances in synovial sarcoma
evaluated by comparative genomic hybridization. Cancer Genet Cytogenet, 115: 39-
46. (1999b).
Speicher, M.R., Gwyn Ballard, S. & Ward, D.C. Karyotyping human chromosomes by
combinatorial multi-fluor FISH. Nat Genet, 12: 368-75. (1996).
Sreekantaiah, C., Ladanyi, M., Rodriguez, E. & Chaganti, R.S. Chromosomal aberrations
in soft tissue tumors. Relevance to diagnosis, classification, and molecular
mechanisms. Am J Pathol, 144: 1121-34. (1994).
Stratton, M.R., Fisher, C., Gusterson, B.A. & Cooper, C.S. Detection of point mutations in
N-ras and K-ras genes of human embryonal rhabdomyosarcomas using
oligonucleotide probes and the polymerase chain reaction. Cancer Res, 49: 6324-7.
(1989a).
Stratton, M.R., Williams, S., Fisher, C., Ball, A., Westbury, G., Gusterson, B.A., Fletcher,
C.D., Knight, J.C., Fung, Y.K., Reeves, B.R. & Cooper, C.S. Structural alterations of the
RB1 gene in human soft tissue tumours. Br J Cancer, 60: 202-5. (1989b).
Suehiro, Y., Umayahara, K., Ogata, H., Numa, F., Yamashita, Y., Oga, A., Morioka, H., Ito,
T., Kato, H. & Sasaki, K. Genetic aberrations detected by comparative genomic
hybridization predict outcome in patients with endometrioid carcinoma. Genes
Chromosom Cancer, 29: 75-82. (2000).
Suwa, K., Ohmori, M. & Miki, H. Microsatellite alterations in various sarcomas in
Japanese patients. J Orthop Sci, 4: 223-30. (1999).
Szepetowski, P., Courseaux, A., Carle, G.F., Theillet, C. & Gaudray, P. Amplification of
11q13 DNA sequences in human breast cancer: D11S97 identifies a region tightly
linked to BCL1 which can be amplified separately. Oncogene, 7: 751-5. (1992).
Szymanska, J., Virolainen, M., Tarkkanen, M., Wiklund, T., Asko-Seljavaara, S., Tukiainen,
E., Elomaa, I., Blomqvist, C. & Knuutila, S. Overrepresentation of 1q21-23 and 12q13-
21 in lipoma-like liposarcomas but not in benign lipomas: a comparative genomic
hybridization study. Cancer Genet Cytogenet, 99: 14-8. (1997).
7 2
Tarkkanen, M., Elomaa, I., Blomqvist, C., Kivioja, A.H., Kellokumpu-Lehtinen, P., Böhling,
T., Valle, J. & Knuutila, S. DNA sequence copy number increase at 8q: a potential new
prognostic marker in high-grade osteosarcoma. Int J Cancer, 84: 114-21. (1999a).
Tarkkanen, M., Huuhtanen, R., Virolainen, M., Wiklund, T., Asko-Seljavaara, S., Tukiainen,
E., Lepantalo, M., Elomaa, I. & Knuutila, S. Comparison of genetic changes in primary
sarcomas and their pulmonary metastases. Genes Chromosom Cancer, 25: 323-31.
(1999b).
Taylor, H.B. & Helwig, E.B. Dermatofibrosarcoma protuberans. A study of 115 cases.
Cancer, 15: 717-25. (1962).
Toguchida, J., Yamaguchi, T., Ritchie, B., Beauchamp, R.L., Dayton, S.H., Herrera, G.E.,
Yamamuro, T., Kotoura, Y., Sasaki, M.S., Little, J.B., Weichselbaum, R.R., Ishizaki, K. &
Yandell, D.W. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas.
Cancer Res, 52: 6194-9. (1992).
Turc-Carel, C., Limon, J., Dal Cin, P., Rao, U., Karakousis, C. & Sandberg, A.A.
Cytogenetic studies of adipose tissue tumors. II. Recurrent reciprocal translocation
t(12;16)(q13;p11) in myxoid liposarcomas. Cancer Genet Cytogenet, 23: 291-9.
(1986).
Vidgren, V., Varis, A., Kokkola, A., Monni, O., Puolakkainen, P., Nordling, S., Forozan, F.,
Kallioniemi, A., Vakkari, M.L., Kivilaakso, E. & Knuutila, S. Concomitant gastrin and
ERBB2 gene amplifications at 17q12-q21 in the intestinal type of gastric cancer.
Genes Chromosom Cancer, 24: 24-9. (1999).
Vogelstein, B. & Kinzler, K.W. The multistep nature of cancer. Trends Genet, 9: 138-41.
(1993).
Vogelstein, B. & Kinzler, K.W. (eds) (1998). The genetic basis of human cancer. McGraw-
Hill.
Warmuth, I. & Moore, P.S. Kaposi sarcoma, Kaposi sarcoma-associated herpesvirus,
and human T-cell lymphotropic virus type 1. What is the current evidence for
causality? Arch Dermatol, 133: 83-5. (1997).
Weber-Hall, S., Anderson, J., McManus, A., Abe, S., Nojima, T., Pinkerton, R., Pritchard-
Jones, K. & Shipley, J. Gains, losses, and amplification of genomic material in
rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res, 56:
3220-4. (1996).
Weiss, S.W. (ed.) (1994). WHO histological typing of soft tissue tumours, 2nd edn.
Springer, Berlin Heidelberg New York.
Whitby, D., Howard, M.R., Tenant-Flowers, M., Brink, N.S., Copas, A., Boshoff, C.,
Hatzioannou, T., Suggett, F.E., Aldam, D.M., Denton, A.S. & al., e. Detection of Kaposi
sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and
progression to Kaposi's sarcoma. Lancet., 346: 799-802. (1995).
7 3
Wiklund, T.A., Blomqvist, C.P., Räty, J., Elomaa, I., Rissanen, P. & Miettinen, M.
Postirradiation sarcoma. Analysis of a nationwide cancer registry material. Cancer,
68: 524-31. (1991).
Wolf, M., Aaltonen, L.A., Szymanska, J., Tarkkanen, M., Blomqvist, C., Berner, J.M.,
Myklebost, O. & Knuutila, S. Complexity of 12q13-22 amplicon in liposarcoma:
microsatellite repeat analysis. Genes Chromosom Cancer, 18: 66-70. (1997a).
Wolf, M., Aaltonen, L.A., Szymanska, J., Tarkkanen, M., Elomaa, I. & Knuutila, S.
Microsatellite markers as tools for characterization of DNA amplifications evaluated by
comparative genomic hybridization. Cancer Genet Cytogenet, 93: 33-8. (1997b).
Wolf, M., Tarkkanen, M., Hulsebos, T., Larramendy, M.L., Forus, A., Myklebost, O.,
Aaltonen, L.A., Elomaa, I. & Knuutila, S. Characterization of the 17p amplicon in
human sarcomas: microsatellite marker analysis. Int J Cancer, 82: 329-33. (1999).
Wooster, R., Cleton-Jansen, A.M., Collins, N., Mangion, J., Cornelis, R.S., Cooper, C.S.,
Gusterson, B.A., Ponder, B.A., von Deimling, A., Wiestler, O.D., Cornelisse, C.J.,
Devilee, P. & Stratton, M.R. Instability of short tandem repeats (microsatellites) in
human cancers. Nat Genet, 6: 152-6. (1994).
Wu, G.J., Sinclair, C.S., Paape, J., Ingle, J.N., Roche, P.C., James, C.D. & Couch, F.J.
17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and
SIGma1B genes. Cancer Res, 60: 5371-5. (2000).
Wunder, J.S., Czitrom, A.A., Kandel, R. & Andrulis, I.L. Analysis of alterations in the
retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas. J Natl
Cancer Inst, 83: 194-200. (1991).
Xie, E., Zhu, Q., Barr, F., Robinson, M., Sferra, T., Muthusamy, R., Qualman, S. & J., D.
The role of the PAX3-FKHR fusion gene in the development of alveolar
rhabdomyosarcoma. Mod Pathol, 14: 4P. (2001).
Zucman, J., Delattre, O., Desmaze, C., Epstein, A.L., Stenman, G., Speleman, F.,
Fletchers, C.D., Aurias, A. & Thomas, G. EWS and ATF-1 gene fusion induced by
t(12;22) translocation in malignant melanoma of soft parts. Nat Genet, 4: 341-5.
(1993a).
Zucman, J., Melot, T., Desmaze, C., Ghysdael, J., Plougastel, B., Peter, M., Zucker, J.M.,
Triche, T.J., Sheer, D., Turc-Carel, C., Ambros, P., Combaret, V., Lenoir, G., Aurias, A.,
Thomas, G. & Delattre, O. Combinatorial generation of variable fusion proteins in the
Ewing family of tumours. EMBO J, 12: 4481-7. (1993b).
Åman, P. Fusion genes in solid tumors. Semin Cancer Biol, 9: 303-18. (1999).
Örndal, C., Mandahl, N., Rydholm, A., Willén, H., Brosjö, O., Heim, S. & Mitelman, F.
Supernumerary ring chromosomes in five bone and soft tissue tumors of low or
borderline malignancy. Cancer Genet Cytogenet, 60: 170-5. (1992).
